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Abstract 
There is an increasing need to demonstrate the return on medical research investment 
through benefit to patients, society and the economy. Patient-reported outcomes 
(PROs), such as quality of life and symptom data, are increasingly collected in clinical 
trials and may provide evidence, which can lead to a range of impacts. However it is 
unclear whether PRO impact is realised in practice. In addition, the different types of 
impact associated with PRO trial results, their barriers and facilitators, and appropriate 
impact metrics are not well defined. 
The doctoral research constituting this thesis adopted a mixed-methods approach with 
the aim of: a) synthesising existing methodological frameworks for healthcare research 
impact; b) determining the range of potential impacts associated with PRO data 
collected in trials, identifying potential PRO impact metrics and barriers and defining 
common facilitators to maximise PRO impact and; c) examining real-world evidence of 
PRO trial data impact and highlight optimal pathways to such impact. A number of 
studies were undertaken to address the aims.   
First, a systematic review of the literature identified 24 existing non-PRO-specific 
frameworks and over 80 impact metrics, which were then synthesised into a novel 
impact matrix and a simplified consolidated methodological framework for use by 
researchers and other stakeholders to help maximise the impact of healthcare research.  
Second, informed by this framework, an additional systematic review sought to 
determine the potential impact of PRO data collected in clinical trials and examined real-
world evidence of PRO trial data impact based on Research Excellence Framework 
(REF). This systemic review suggested that PRO trial data has the potential to inform 
clinical practice, clinical guidelines and, health policy; support drug approval, pricing and 
reimbursement decisions and; inform clinical and shared decision-making and consent 
for treatment. Furthermore, this second systematic review highlighted perceived 
methodological problems regarding the design, conduct and analysis and reporting of 
PRO data from clinical trials; which may hinder the impact of PRO data from clinical 
findings. Potential facilitators aimed at maximising PRO trial impact were also identified. 
The review identified 12 (n=69, 17%) REF 2014 impact case studies, which reported 
impact directly attributable to PRO findings. Including changes to international clinical 
guidelines and national guidelines, influencing cost-effectiveness analysis and drug 
approvals.   
Finally, in order to gain deeper understanding about the topics identified in the second 
systematic review, 24 semi-structured qualitative interviews were conducted with 
international stakeholders. Interviewees suggested PRO trial findings could lead to 
impact in the five impact categories identified in the aforementioned ‘pathways to 
research impact’ methodological framework. However, it was suggested that broader 
international stakeholder collaboration is required to tackle existing barriers and 
maximise the realisation of PRO trial impact on patients and society. 
In conclusion, this thesis has identified a range of potential impacts from PRO data 
which may benefit patients and society.  However, a number of barriers need to be 
addressed to fully realise these benefits. This research highlights that the measurement 
of research impact, and specifically PRO research impact, is an essential exercise to 
better allocate limited funding, provide accountability and minimise research waste. 
Nonetheless, determining and implementing impact metrics is a complex task and will 
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Introduction to the research 
The research within this thesis focuses on the impact of healthcare research and 
specifically, patient reported outcome (PRO) data collected in clinical trials. The aim 
of this chapter is to provide a general background and justification for the research; 
and to outline the aims, objectives and structure of the thesis. 
Background  
A. Clinical trials  
Randomised controlled trials (RCTs) are considered the ‘gold standard’ tool for 
determining the efficacy and cost-effectiveness of healthcare interventions [1]. In 
RCTs, participants are randomly allocated to two or more groups in order to 
statistically test a clinical intervention. One of the intervention groups is referred as 
the ‘experimental’ or ‘treatment’ group, while the other is known as the ‘control’ 
group. The control group can receive a placebo (i.e. dummy drug), usual care, or no 
intervention [2]. Outcomes are measured at specific time points and the difference in 
outcomes between the groups is statistically assessed [3]. 
In clinical trials, the outcomes of interest are often defined as primary and secondary 
outcomes or endpoints. The primary outcome refers to the main measured variable 
(e.g. progression free survival or improvement in clinical signs or symptoms such as 
fatigue) based on the primary hypothesis of the intervention. The primary endpoint 
should be ‘the variable capable of providing the most clinically relevant and 
convincing evidence directly related to the primary objective of the trial’ [4, 5]. The 
primary endpoint refers to the analysed parameter (e.g. change-from-baseline at 6 
weeks in mean fatigue score) [6]. Secondary endpoints assess additional effects of 
the intervention, side effects or tolerability and may be used to support the primary 
endpoint [4, 7]. All other types of endpoints are referred as exploratory endpoints. 
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Exploratory endpoints include outcomes that are unlikely to show an effect but are 
included to evaluate new hypotheses or clinical important events that are expected 
to occur too infrequently to show a treatment effect [8]. In order to ensure that any 
outcomes are identified in line with the proposed hypothesis it requires sufficient 
power to capture those changes. The number of participants involved in a trial is 
determined by the power needed to identify a real difference in the primary endpoint 
[8].  
Clinical trials should possess internal and external validity if the results are to inform 
patient care. Internal validity refers to what extent the treatment effects are attributed 
to differences in treatment and not confounding (i.e. differences in baseline 
characteristics between treatment groups that influence treatment and outcome 
measures)  [9]. To achieve optimal trial design and conduct, confounding factors and 
bias must be reduced to a minimum. Bias is defined as a systematic error or any 
deviation of the study outcomes from the ‘truth’ [10]. Careful consideration should be 
given to randomisation, allocation concealment, blinding and loss to follow up to 
minimise bias [10]. External validity or generalisability refers to whether the 
outcomes of the trial can be applied to other setting and patients [9, 11]. While the 
design and conduct of the study are important to ensure the quality of the clinical 
trial, it is also important to ensure that outcomes reflect the patient’s experiences.  
B. Clinical Trials and Patient-Reported Outcomes 
One of the important ways of capturing outcomes in clinical trials is through the use 
of patient reported outcomes (PROs). PRO is an ‘umbrella’ term, defined by the U.S. 
Food and Drug Administration (FDA) as “any report of the status of a patient’s health 
condition that comes directly from the patient, without interpretation of the patient’s 
response by a clinician or anyone else” [12]. Clinical trials often assess outcomes 
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such as mortality and morbidity, disease exacerbation or clinical events. Although 
these clinical outcomes are of great importance, PROs are increasingly collected in 
clinical trials to provide evidence of the impact of disease or treatment on patient 
health-related quality of life (HRQL) or symptom severity [13]. HRQL is a multi-
dimensional concept that describes or characterises the effect of a disease or 
treatment on a number of domains that capture a patients’ physical functioning, 
psychological impact and social functioning  [13, 14]. Although HRQL is considered a 
PRO, the terms should not be used interchangeably. The term PRO refers to the 
source of the report – i.e. the patient; whereas HRQL refers to the concept or content 
of the report [15]. Between 2007 and 2013, 27% of the clinical trials registered in 
ClinicalTrials.gov collected PRO data [16]. PRO data in clinical trials is collected 
through self-reported questionnaires known as PRO measures or ‘PROMs’ [14, 17, 
18]. Broadly, PROMs can be classified as disease-specific or generic instruments 
[14, 19]. The former can be tailored to specific conditions, populations, or certain 
functions; such as the Oxford Hip Score (OHS) [19, 20]. Generic instruments or 
‘measures of health status’ focus on general aspects of HRQL, irrespective of the 
disease or condition of the patient [20, 21]. These measures are not designed to 
assess disease specific effects. Therefore, they might not be suitable to detect small 
treatment effects [14]. A frequently used generic measure is the 36-Item Short Form 
Survey (SF-36) [21]. Disease specific measures are often considered to have greater 
validity and credibility and are more relevant to patients; whereas generic measures 
allow comparison between different conditions [19]. 
Trial participants are asked to self-complete PROM questionnaires, which may be 
available in a number of different formats e.g. paper-based or electronic. These may 
be completed at different time-points during the study without influence from a third 
5 
 
party e.g. clinician. This type of data can often provide valuable additional 
information on the impact of side effects from therapeutic interventions on a patient’s 
HRQL. PROs may capture information about benefits or harms that could be 
overlooked using conventional clinical measures [22]. PROs are used as a way to 
define and measure endpoints in clinical trials. In addition, they can also provide 
valuable evidence on the efficacy, effectiveness and tolerability of interventions to 
drug/device approvals, labelling claims and reimbursement [12, 23, 24].  
In clinical trials, health utility PROMs are used to determine patients’ preference 
values on their health status, which are widely used in cost-effectiveness and cost-
utility analysis [14, 18, 25]. Single item measures include a single aspect of one PRO 
instrument. For instance, the item might ask the patients to rate their health on a 
seven-point scale ranging from very poor to excellent. These measures are less 
burdensome to collect; however, they are not widely used as their reproducibility, 
reliability and precision of measurement may be compromised [26]. The European 
Quality of Life Instrument – 5 Dimensions (EQ-5D) is the most common generic 
instrument and assesses: mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression [27]. Utility measures characterise the effects of an intervention 
into a value between 0 (death) and 1 (perfect health) [25]. There may be situations in 
which utility falls below 0, meaning that the health status is perceived as worse than 
death.  
The answer given to the five domains of the EQ-5D are transformed to generate a 
summary score, which indicates the overall utility. Health utility can be combined with 
survival data to generate quality adjusted life years (QALYs) [28]. QALYs are 
incorporated in clinical trials to enable comparison among healthcare interventions 
and inform cost-effectiveness.  
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Cost-effectiveness analysis expresses value for money in terms of incremental cost-
effectiveness ratio (ICER), which is calculated as the difference in costs divided by 
the difference in QALYs (health utility) gained. In the UK, the use of QALYs is 
required by the National Institute for Health and Care Excellence (NICE) to inform 
health technology assessment (HTA) [29]. During the NICE appraisal process, the 
ICER is compared with a £20,000 to £30,000 threshold per QALY to determine 
whether the health intervention represents an efficient use of resources [30]. A 
health intervention is considered ‘economically dominant’ when total costs are lower 
compared to standard care and clinical outcomes are improved. 
In addition, some cost-effectiveness analyses rely on mapping of disease specific 
HRQL data to generate health utility values. For instance, Tocilizumab a drug used 
to treat systemic juvenile idiopathic arthritis was approved by NICE based on the 
health utilities submitted by the manufacturer and improvements in function, 
increased quality of life and reduction in joint damage. The health utilities were 
mapped from the Child Health Assessment Questionnaire (CHAQ) scores, using a 
mapping formula derived in adults rheumatoid arthritis that mapped Health 
Assessment Questionnaire [HAQ] results onto EQ-5D utilities [31, 32].  
PROs may be assessed as primary, secondary or exploratory endpoints within a trial 
depending on the study aims and objectives [23]. Although PROs are used to 
measure disease-specific symptoms and aspects of functioning directly related to a 
disease or HRQL. For example, PROs consistently serve as primary endpoints in 
psychiatric disorders, palliative care and in painful conditions, such as migraine and 
gastrointestinal disorders [12, 23, 33, 34]. However, it is still relatively uncommon to 
incorporate PROs as primary endpoint. PROs are more often included in trials as 
secondary or exploratory outcomes to provide patient-centred assessment of 
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treatment benefits and toxicity [35, 36]. For instance, among the 13,584 oncology 
trials registered in ClinicalTrials.gov between 2007 and 2013, only 2,453 (18%) of 
the trials listed PRO as an outcome measure. Of these 5% and 13% were primary 
and secondary outcomes, respectively [16].   
PROs included as secondary outcomes provide ‘added value’ data that may contrast 
with or may support the primary outcome of the study [33, 36]. Such ‘value’ has the 
potential for securing labelling claims and in providing supportive information for 
reimbursement [33, 37-39]. Increasingly PROs are not only used to measure efficacy 
but also to assess the tolerability and safety of interventions through the assessment 
of patient reported adverse events/symptoms [40], using tools such as the National 
Cancer Institute's  patient’s adverse event monitoring (Patient Reported Outcomes-
Common Terminology Criteria for Adverse Events (PRO-CTCAE) [41, 42]. In 
addition, PROs may be incorporated as a secondary endpoint to satisfy health HTA 
and regulatory requirements around the demonstration of economic value [23, 33].  
C. The importance of PROs in clinical trials 
PRO trial data can be used to inform patients, clinicians, payers and policy-makers 
about the impact of a health intervention and its effects, specifically symptoms, 
functioning and/or HRQL [18, 35, 41, 43]. For instance, PRO data can provide 
relevant information surrounding how patients with the same condition feel during 
and after a treatment, which cannot be gained by clinical outcomes alone [36, 44]. In 
addition, they can help provide information around patient-centred benefits and side 
effects of a treatment, helping patients to choose the right intervention for them [34-
36]. As an example, head and neck cancers are often associated with severe side-
effects that can have a profound impact on quality of life [45-47]. Surgery is used as 
the primary treatment resulting in disfigurement, social withdrawal, anxiety and poor 
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quality of life [44, 48]. Radiotherapy, also used as primary treatment, administrated 
alone or in combination with surgery or chemotherapy, can result in oral mucositis 
amongst patients [44, 49] This is associated with severe side effects such as pain, 
difficulty swallowing, taste changes, vocal problems and poor quality of life [44]. 
Therefore, assessment of PRO trial data is essential to inform patients about their 
treatment options and to provide evidence-based symptom management therapies, 
supportive care and rehabilitation.   
PRO trial data can also be used to inform pharmaceutical labelling claims and drug 
approval [12]. PRO data may help patients and clinicians understand the risks and 
benefits of a treatment [50]. For instance, ruxolitinib (Jakafi) was approved by the 
FDA on the basis of PRO data information that was included in the labelling claim 
[51]. This oncology drug, used to treat myelofibrosis, was approved based on the 
reduction in spleen volume and improvement from baseline to week 24 in total 
symptom score, as measured with the modified Myelofibrosis Symptom Assessment 
Form version 2.0 (MFSAF v2.0) [51, 52]. The core symptoms of myelofibrosis 
captured through the MFSAF v2.0 were abdominal discomfort, pain under ribs, night 
sweats, itching, bone/muscle pain and early satiety (feeling full) [52]. 
PRO data can also inform and influence healthcare policy and practice. PRO data 
should be considered in the development of evidence-based guidelines, as it may 
help identifying unmet needs [53]. In addition, PRO evidence from trials may be used 
to inform healthcare practice at individual level. For example, shared decision-
making regarding treatment for an individual patient [54]. 
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D. PROS in clinical routine practice 
Beyond trials, PROs are also increasingly used in routine clinical practice [55, 56]. 
PRO data can be used to improve healthcare organisation and delivery through the 
assessment and comparison of providers’ performances [55, 57, 58]. Furthermore, 
PROs can be utilised at an individual patient level, capturing data throughout the 
care pathway, for instance to better understand the impact of a condition/disease 
and its treatment on patient HRQL, inform shared decision making and improve 
healthcare management and outcomes. Routine use of PROMs in clinical care can 
be used to monitor a patient’s progress, and act as an early warning of potential 
problems, facilitating prompt clinical intervention. Studies have shown that this 
routine use improves patients’ satisfaction with their care and symptom 
management, and can improve their quality of life and survival rates [59, 60]. 
Clinicians also reported that they felt the routine use of PROMs improved the 
consultation, helped reduce their burnout and reduced the burden on them through 
better work efficiency [61, 62]. Thus PROMs, promoted the provision of better quality 
of care, shared clinical decision-making, and better utilisation of health resources 
[58, 63]. 
E. Research waste and impact 
“We need less research, better research, and research done for the right reasons” 
Altman, D., 1994 
 
In 2010, US$240 billion were invested in health research worldwide [64]. It was 
estimated that about 85% of healthcare research investment in 2009 was wasted 
[64]. The most common causes of this waste stemmed from conducting unnecessary 
research, the selection of inadequate research questions, ‘poor quality’ research 
design and methods, failure to publish research on time, ‘poor quality’ reporting and 
10 
 
lack of dissemination [64-66]. Making available misleading research is arguably 
considered as unprofessional, unethical and unacceptable [67]. 
Although some research waste is inevitable, it is important to improve the efficiency 
and impact of research to maximise the benefit of funding allocated to healthcare 
research [65, 68]. Therefore, it is important that the research community provide 
evidence to inform and justify the funding allocated by sponsors, funders and 
academic institutions [69]. Assessing healthcare research impact is an essential 
exercise to ensure that research questions are relevant to policy and practice, and to 
demonstrate accountability and research benefits [69, 70]. The Higher Education 
Funding Council for England (HEFCE, 2014), defines research impact as “an effect 
on, change or benefit to the economy, society, culture, public policy or services, 
health, the environment or quality of life, beyond academia” [71].   
In general, methodological frameworks propose to measure research impact through 
four different approaches: i) academic-orientated frameworks, ii) interaction process 
between stakeholders and researchers, iii) partnership between researchers and 
policy-makers and iv) evaluation of the pathways to impact [72]. Measuring research 
impact is complex, indirect and hard to attribute. However, it is an essential exercise 
to inform limited resources allocation, maximise research impact and minimise 
research waste. Short-term benefits of research are easier to attribute whereas long-
term benefits are more difficult to capture as they are slow to emerge, hard to 
measure and sometimes unexpected [69, 73]. 
Currently, the measurement of healthcare research impact is predominantly 
undertaken in Canada, Australia and the United Kingdom (UK) [69]. For instance, in 
the UK, the Research Excellence Framework (REF) has been adopted to assess 
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academic research impact in the higher education sector. The REF is a review 
process undertaken by expert panels (senior academics, international members and 
research users) who evaluate the impact of research reported in those case studies 
submitted by UK Higher Education Institutions (HEIs) [71]. Examples of other 
available methodological frameworks include the Payback Framework used to 
assess health research impact through academic outputs and wider societal benefits 
[70]; the SIAMPI model (Social Impact Assessment Methods for research and 
funding instruments through the study of Productive Interactions between science 
and society) focused on productive interactions, especially exchanges between 
researchers and stakeholders [74] and the Research Contribution Framework, which 
uses contribution analysis to explain influence in policy and practice [75]. 
Nonetheless, there is a lack of consensus around what are the most appropriate 
frameworks and impact measures by which to monitor the impact of healthcare 
research, demonstrate benefits of conducting research and accountability [69, 72], 
especially in studies utilising PROs. 
While preventing research waste is important, it is also important that results of 
healthcare research, such as clinical trials, are available to inform future healthcare 
research and clinical practice and provide an evidence base to support decision-
making and clinical guidelines [65, 76]. A recent study reviewing patterns of 
publication of clinical trials funded by US National Institutes of Health (NIH) in peer-
reviewed journals, demonstrated that between 25% and 50% of the clinical trials 
were never published [76]. Non-reporting of trial data represents further source of 
research waste, as results might be duplicated or not implemented into clinical 
practice [66, 76].  
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Justification for research 
PROs have the potential to lead to a range of impacts including improving health 
outcomes for patients, if collected and analysed in clinical trials and adequately 
reported in the literature [77, 78]. PRO trial results, if captured in a scientifically 
rigorous way, should therefore exert considerable impact on future patient care, 
informing decision-making in the clinical setting, supporting pharmaceutical labelling 
claims and influencing healthcare policy [12, 21, 34, 79-81]. However, empirical 
evidence investigating the range of potential impact associated with PRO data 
collected in trials, real-world evidence of PRO trial impact, potential PRO impact 
metrics, common barriers and facilitators to maximising PRO impact and optimal 
pathways to PRO impact is lacking.  
Recent research suggests important PRO protocol-specified hypotheses, data 
collection methods and statistical plans are often sub-optimal, missing data rates are 
high and PRO findings are routinely excluded from arising trial publications [35, 81, 
82]. There is growing evidence that there is substantial research waste in relation to 
PROs. The recent EPIC study (evaluation of patient-reported outcome protocol 
content and reporting in UK cancer clinical trials) demonstrated that relevant PRO 
protocol items are frequently omitted and non-reporting of PRO findings was 
widespread. In addition, where PRO data was published, it was often significantly 
delayed and reporting quality suboptimal [83]. This could lead to inconsistent 
assessment of important patient-centred outcomes [84], risking biased and 
unreliable trial results with high levels of missing data [85]. Thus, compromising the 
impact of PRO trial data on future patient care. This practice may reduce the impact 
on future patient care; mislead healthcare policy and waste limited healthcare and 
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research resources [65, 80, 84]. Therefore this study set out to determine the impact 
of PRO trial results on future patient care and society. 
Aims 
The aim of this thesis was to a) synthesise existing methodological frameworks for 
healthcare research impact; b) determine the range of potential impact associated 
with PRO data collected in trials, identify potential PRO impact metrics and define 
common barriers and facilitators to maximising PRO impact and; c) examine real-
world evidence of PRO trial impact and highlight optimal pathways to such impact. 
Objectives 
A. To identify impact frameworks and metrics aimed at measuring and maximising 
the impact of healthcare research. 
B. To determine the range of potential impact from PRO data from clinical trials. 
C. To identify potential PRO impact metrics and determine common barriers and 
facilitators to maximising PRO impact.  
D. To assess Research Excellence Framework (REF) impact case studies to 
explore real-world evidence of PRO trial impact and highlight optimal pathways to 
such impact. 
E. To explore in-depth international stakeholders’ perspectives about the range of 
potential impacts of PRO clinical trials and impact metrics and; barriers and 
facilitators to maximise the impact of PRO trial data.  
Structure 
The thesis presented different studies to address the objectives detailed above: 
 Chapter 3, presents a systematic review (published in PLOS Medicine in 
2017) focused on determining existing, non-PRO-specific, methodological 
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frameworks and metrics to measure the impact of healthcare research. This 
addresses objective A. 
 Chapter 4 presents an additional systematic review (currently under review in 
a peer-reviewed journal). This chapter determines the potential impact of 
PRO data collected in clinical trials and assess real-world evidence of PRO 
trial data based on REF 2014 case studies. This addresses objectives B, C 
and D. 
 Chapter 5 presents a qualitative study exploring international stakeholders’ 
views on the current impact of PRO data collected in clinical trials. This 
chapter discusses the principal findings of the research and their implications, 
highlights strengths and limitations of the research and provides 
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The aim of this chapter is to provide a general overview of the mixed-methods 
approach used to answer the objectives and aims of this doctoral research. 
Justification of the choice of methods and alternative methods considered are also 
discussed. Further detail on the methods used are presented in Chapters 3 and 4 
and related appendices. The qualitative methods used in Chapter 5 are described in 
greater detail in this chapter (albeit some further information on methods is also 
presented in chapter 5) to provide greater depth and transparency that are not 
afforded in the word limitations of the manuscript presented in chapter 5. 
The aims of the thesis were to a) synthesise existing methodological frameworks for 
healthcare research impact; b) determine the range of potential impact associated 
with PRO data collected in trials, identify potential PRO impact metrics and define 
common barriers and facilitators to maximising PRO impact and; c) examine real-
world evidence of PRO trial impact and highlight optimal pathways to such impact. 
The thesis incorporated qualitative and quantitative methods (mixed-methods 
approach) of data collection and analysis to answer the objectives of this doctoral 
research [1, 2]. The use of the mixed-methods approach provided a more complete 
understanding of the research question, as this approach allowed the thesis to draw 
on the strengths of both qualitative and quantitative methods [1, 3]. Table 1 depicts 




Table 1. Mixed-methods research process 
Knowledge gap Aims Methods 
Lack of consensus around 
the most appropriate method 
to measure healthcare 
research impact 
To identify the most 
appropriate ways of 
measuring healthcare 
research impact by 
synthesising existing 
methodological frameworks 
for healthcare research 
impact  
Systematic review and 
synthesis of methodological 
healthcare impact 
frameworks (Chapter 3) 
Lack of evidence on how 
PRO data impact from 
clinical trials is utilised   
To determine the range of 
potential impact associated 
with PRO data collected in 
trials, identify potential PRO 
impact metrics and define 
common barriers and 
facilitators to maximising 
PRO impact 
Systematic review and 
synthesis of the potential 
impact of PRO data from 
clinical trials and identify 
barriers and facilitators to 
maximising PRO impact 
(Chapter 4) 
Limited evidence regarding  
real-world impact of PRO 
trial data and optimal 
pathways to maximise such 
impact 
To examine real-world 
evidence of PRO trial impact 
and highlight optimal 
pathways to such impact 
 
To explore international 
stakeholders’ perspectives 
surrounding the impact of 
PRO trial data and barriers 
and facilitators upon patients 
and society through 
qualitative interviews with 
key stakeholders (Chapter 5) 
 
Systematic reviews  
A. Introduction 
Systematic reviews are considered to be an efficient method of integrating large 
numbers of critical pieces of information. This information is aggregated into a 
manageable and cohesive review in order to answer a specific question and allow 
rational decision making [4, 5]. Systematic reviews use explicit methods to search, 
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critically appraise and synthesise relevant literature systematically [4, 6]. Thus, two 
systematic reviews were undertaken to answer objectives A, B, C and D of the 
thesis. The first systematic review (Chapter 3) focused on objective A: identifying 
impact frameworks and metrics to measure and maximise the impact of healthcare 
research. The second systematic review (Chapter 4) focused on objective B: 
determining the range of potential impacts of PRO data collected from clinical trials, 
objective C:  identifying potential PRO impact metrics and determining common 
barriers and facilitators to maximising PRO impact; and objective D: assessing 
Research Excellence Framework (REF) 2014 impact case studies to explore real-
world evidence of PRO trial impact and highlight optimal pathways to such impact. 
Both reviews were conducted and reported according to the ‘Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses’ (PRISMA) statement, used by the 
Cochrane Collaboration [7]. Further details on methods can be found in Chapter 3, 
page 6 of the publication and Appendix 1.1 and Chapter 4, Appendix 2.1 
B. Justification for choice of methods 
Systematic reviews are considered the highest level of evidence in research 
evidence hierarchies [7]. They are used by health providers, researchers and policy 
makers to evaluate the evidence on effectiveness of healthcare interventions to 
enable informed decision-making [8-10]. Systematic review are a fundamental 
scientific technique that seeks to answer a clearly defined research question by 
following a transparent and reproducible pre-specified methodology [8]. Furthermore, 
systematic reviews attempt to identify all existing studies that meet the pre-defined 
eligibility criteria; with the purpose of systematically identifying, appraising and 
synthesising research evidence, whilst minimising selection bias. If applicable, 
systematic reviews can present a statistical summary of the findings in a meta-
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analysis [6, 8, 11].  However,  systematic reviews can be time consuming, costly to 
carry out and, require considerable effort and resource to ensure they are 
comprehensive [8, 10]. 
Systematic reviews often adhere to the Cochrane Collaboration guidelines [6] and 
the Centre for Reviews and Dissemination (CRD) on how to conduct a review [12]. 
Additionally, prospective registration of medical research and medical systematic 
reviews is recommended to avoid duplication, reduce research waste and increase 
transparency [9, 10, 13]. PROSPERO, the international prospective database 
register for systematic reviews, has the aim of providing lists of a priori registered 
health and social care protocols of systematic reviews. In order to reduce the risk of 
duplication and selective reporting, by enabling comparison between the 
prospectively submitted protocol and the completed review [10, 14].  
C.  Alternative methods 
There are alternative methods that could have been used to synthesise the existing 
literature. The most common methods are rapid and narrative (non-systematic) 
literature reviews, which are described below: 
Rapid reviews are valuable to synthesise evidence in a short timeframe for informing 
decision-makers of a specific end-user, usually healthcare and policy makers [15, 
16]. Nonetheless, there is no clear consensus around the methodology rapid reviews 
follow. In general, the methodology is not as rigorous as that followed by full 
systematic reviews, potentially raising the risk of bias [15, 17]. Common types of bias 
include: a) selection bias, which refers to the lack of inclusion of relevant literature; b) 
author bias, which refers to the inclusion of articles that are of interest to the author; 
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and c) publication bias, which refers to the publication or non-publication of the 
results, depending on the obtained findings [6, 18]. 
The literature searches conducted within rapid reviews might be limited to a smaller 
number of databases, whereas systematic reviews attempt exhaustive literature 
searches [6, 19]. In many rapid reviews, the research evidence included is not 
critically appraised and the synthesis of the results does not provide depth of 
information and recommendations [16]. Consequently, rapid reviews should be 
carefully interpreted as their limited transparency regarding methodology and 
reporting raises the risk of certain types of bias (e.g. author, assessment, selection 
and publication bias), which if eventually present may undermine validity and utility of 
the findings [15, 16]. 
Non-systematic narrative literature reviews attempt to summarise evidence about a 
general research question [20, 21]. This method can be more time efficient and less 
resource-intensive than a full systematic review. However, the methodology followed 
is not pre-specified and clearly described. For instance, the search strategy is not 
pre-specified, a systematic way to conduct the search strategy is not followed and 
the findings may not be critically appraised and validated [21], rising the risk of bias. 
Therefore, the findings may not be reproducible, published and may not support 
evidence-based practice [20, 21].  
Directed content analysis  
A. Introduction 
In Chapter 4, a systematic review was conducted to answer thesis objective B: to 
determine the range of potential impacts of PRO data collected from clinical trials, 
objective C: identify potential PRO impact metrics and determine common barriers 
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to maximising PRO impact and; objective D: assess Research Excellence 
Framework (REF) 2014 impact case studies to assess real-world evidence of PRO 
trial data impact and determine facilitators aimed at maximising PRO trial data 
impact. In order to extend the conceptual ‘pathways to research impact’ 
methodological framework developed in Chapter 3, directed content analysis was 
used. 
B. Justification for choice of methods 
Directed content analysis aims to validate or extend/refine a conceptual theory, 
which refers to basing new research on previous knowledge [22-24]. This approach 
was chosen, as it is considered a transparent and comprehensive method, which 
may enhance the rigour of data analysis and comparison of the results across the 
included studies [22, 24]. Directed content analysis uses predetermined codes to 
label the data. New categories and subcategories are created when the data cannot 
be coded under the existing structure, which allows capture of all the events that 
explain a phenomenon (exhaustiveness) [22, 24]. This method was chosen as the 
predetermined codes used to analyse the included articles and case studies were 
contained in the aforementioned ‘pathways to research impact’ methodological 
framework [25]. One of the main limitations of directed content analysis is the use of 
prior information available to the researcher, which can result in the introduction of 
confirmation bias, which might lead to the identification of supportive evidence rather 
than information that might not support a conceptual theory [22]. To mitigate this, 
regular meetings with experts on the topic were held to review and examine the 
categories and subcategories created before and during the coding stage [22]. 
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C. Alternative methods 
An alternative method considered was conventional content analysis. Content 
analysis is appropriate when an existing theory or range of literature is limited [24]. 
However, this approach does not focus on the refinement of an existing 
methodological framework. Although conventional content analysis allows the data to 
be categorised into themes (inductive category development), it does not incorporate 
the use of predetermined categories [22]. Furthermore, directed content analysis 
follows a more structured process that results in a more comprehensive and 
exhaustive data analysis, as detailed in Chapter 4, page 54. Therefore, conventional 
content analysis would not be useful in answering objectives B and C of the thesis, 
as this method would not enable direct incorporation and refinement of the ‘pathways 
to research impact’ methodological framework.   
Systematic Evaluation of Research Excellence Framework Case Studies 
In Chapter 4, the Research Excellence Framework (REF) 2014 case studies 
database was assessed in order to identify real-world evidence of PRO trial impact. 
The REF 2014 database was chosen as it provided a robust national database for 
identifying impactful PRO clinical trials, objective C of the thesis. 
A. Introduction 
The REF is a system for assessing the quality of research in UK HEIs [26]. REF 
impact case studies, aggregated in the REF 2014 database, are four-page 
documents divided into: i) summary of the impact, ii) underpinning research, iii) 
references to the research, iv) details of the impact, and iv) sources to corroborate 
the impact. Thus, case studies describe the research undertaken and its arising 
impact, whilst providing supportive evidence [26]. According to the REF, impact is 
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defined as “changes and benefits to the economy, society, culture, public policy and 
services, health, the environment and quality of life beyond academia” [26]. 
The case studies were categorised in 36 subject areas (units of assessment, UOA) 
and are aggregated into four main areas (Main Panel A, B, C and D). The systematic 
review conducted in Chapter 4 focused on Main Panel A, as it encompasses clinical 
areas more likely to retrieve information on PRO trial impact. The UOA within Main 
Panel A were: 
 
Units of Assessment (UOA) 
Main 
Panel A 
1 Clinical medicine 
2 Public Health, Health Services and Primary Care 
3 
Allied Health Professions, Dentistry, Nursing and 
Pharmacy 
4 Psychology, Psychiatry and Neuroscience 
5 Biological Sciences 
6 Agriculture, Veterinary and Food Science 
 
B. Justification for choice of methods 
The REF 2014 database is an indexed text search engine that retrieves impact case 
studies based on an entered search criteria. The REF 2014 database allows one to 
run simple, Boolean, directed and wildcard searches. Furthermore, the database 
provides a collection of tag terms that are applied to each case study and are used 
to refine results. The tags included were: submitting institution, unit of assessment, 
summary impact type, research subject area, impact global location, impact UK 
location and interdisciplinary [27]. For search strategy details see Chapter 4, 
Appendix 1.  
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One of the main strengths of the REF 2014 database is that the case studies 
included represent research judged to be of the highest quality conducted and 
submitted by the UK HEIs. 6,695 case studies were submitted; however, only 6,637 
were authorised for ‘publication’, since the remaining presented confidential 
information. In addition, the case studies presented meaningful, far-reaching and 
properly articulated impact, which was demonstrated through convincing evidence. 
Moreover, the impact focused on the benefits of research rather than the pathways 
to impact, allowing the assessment of real-world impact on society from a particular 
research study [28]. Therefore, the case studies were considered by the authors as 
the best available information to assess and demonstrate the impact of PRO trial 
data.  
However, one of the main limitations is that not all the PRO clinical trials in which UK 
HEIs have participated may have been included in the REF 2014 database; hence, 
some examples could have been missed. This exclusion was a consequence of the 
assessment criteria implemented by the REF expert panel and the skills of the 
submitting HEIs to articulate and demonstrate research impact. In addition, the REF 
case studies were led by UK HEIs which also could have led to the exclusion of key 
impactful international PRO clinical trials. Lastly, the REF 2014 requested from HEIs 
to link impact to specific high quality research outputs (e.g. socioeconomic impacts) 
resulting in the exclusion of impact on industry, public engagement and policy 
advice, which are expected benefits of research. The REF 2021 will provide the 
opportunity for HEIs to demonstrate research impact through these areas [29]. 
C. Alternative methods 
An alternative method to the use of the REF 2014 database would have been to 
conduct a systematic review of all the existing PRO clinical trials. The advantage of 
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adopting this approach would have been a bigger and more representative sample of 
included studies, which would have included more than UK-based research. 
However, it would not have been possible to review the impact of all PRO clinical 
trials within the timeframe of the PhD as there are a huge number of such trials, 
26,337 (27%) of the registered trials in ClinicalTrials.gov database [30]; and trial 
publications/reports do not routinely include information on impact, making it very 
difficult to evaluate. We therefore decided to use the REF 2014 sample, as it was 
more manageable to review during the PhD process, but would still provide a 
representative sample of UK PRO clinical trials research and include information on 
purported impact, objective D of the thesis. 
Reviewing documents such as clinical guidelines and FDA or EMA drug approvals 
was also considered as an additional method; however, this could have limited the 
identification of certain types of impact to changes in clinical guidelines and PRO 
labelling claims approvals, rather than looking at the broader range of impacts 
associated with PRO trial data.  
The use of qualitative methods exclusively was considered in determining the 
potential and real-world impact of PRO data collected from clinical trials (objectives 
B, C and D). However, they were deemed unsuitable as qualitative methods aim at 
developing concepts to better understand and interpret social phenomena in natural 
settings [31, 32]. This was not appropriate for these objectives, as it was necessary 
to conduct a systematic review prior to the use of qualitative techniques to better 
understand the range of impacts of PRO clinical trials. Qualitative research was used 
sequentially to complement areas not amenable to the conducted systematic reviews 





This section outlines the methods used to answer objective E of the thesis: to 
explore in-depth international stakeholders’ perspectives about the range of potential 
impacts of PRO clinical trials and impact measurement metrics, and barriers and 
facilitators to maximise the impact of PRO trial data. The methods were as follows: 
A) ethical approval, B) sampling and recruitment procedure, C) data collection, and 
D) data analysis. 
The results of the systematic review ‘The impact of patient-reported outcome (PRO) 
data from clinical trials: a systematic review and critical analysis’ (Chapter 4) 
suggested that PRO trial findings had the potential to inform clinical practice, clinical 
guidelines and health policy; support drug approval, pricing and reimbursement 
decisions and; inform clinical decision-making, shared decision-making and consent 
for treatment. 
However, the systematic review did not provide detailed information on the different 
types of impact identified and only a few impact metrics were presented to measure 
such impact. The barriers and facilitators for maximising PRO trial data impact were 
only superficially identified (‘thin’ data) [32]. In order to have a better understanding 
of the potential facilitators and barriers which would maximise PRO trial data impact, 
qualitative methods were considered to generate ‘rich’ data (deeply nuanced 
description, interpretation and meaning of data or events [33]). Therefore, one-to-one 
semi-structured interviews were identified as an appropriate data collection method 
to explore the perspectives of international stakeholders involved in the use or 
review of PRO trial data (Chapter 5).  
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A. Ethical approval 
The research followed the University Code of Practice for Research and Data 
Protection and Handling Guidelines [34]. Ethical approval was granted by The 
University of Birmingham Research Ethics Committee in December 2016 (ERN_16-
0806) for the qualitative work (Chapter 5).  
a) Consent  
A ‘participant information sheet’ was sent to the participants before the interview. 
The participant information sheet provided a brief and clear summary about the 
qualitative study such as; the objectives of the research, participant’s responsibilities 
and potential risks. Additionally, it allowed the participants to decide whether the 
study was of interest and whether they wished to discuss it further.  
At the beginning of the interview, participants were asked if they read and 
understood the information sheet. Furthermore, participants were offered the 
opportunity to ask questions about the study to ensure they were fully informed 
about the study prior to providing formal consent for the use of their anonymised 
data. Verbal consent was taken and recorded if the interview was conducted over 
the phone, whilst written consent was taken during face-to-face interviews. 
Participants were informed they had the right to stop the interview at any time with 
the option of destroying the interview recording and removing it from the analysis if 
they so wished, up to 10 days after the interview.  
b) Participant withdrawal  
Participants were able to withdraw without giving a reason up to 10 working days 
after the interview. This period was considered to be enough for the participants to 
decide whether they still want to be part of the study and for the research team to 
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prepare the collected data for analysis. After this point, data were integrated into the 
analysis and it was therefore not possible to disaggregate the information. 
Participants were informed of this before the interview had taken place in the 
participant information sheet and reiterated before confirming verbal consent at the 
beginning of the telephone interview. 
c) Confidentiality  
Semi-structured interviews were digitally recorded. Recordings were removed from 
the recording device as soon as they were uploaded to the secure, password-
protected encrypted University server, which is backed up automatically. Once 
anonymised transcripts were produced, the recordings were destroyed and deleted 
from the server. Transcripts were produced from the interviews by a transcription 
company and stored in the same way as the interview recordings. Transcripts, with 
identifiable information removed, were stored on the University server. 
In order to ensure confidentiality of the data, a unique participant ID code was 
assigned to the participants. The telephone or email addresses provided by 
participants were only used to arrange the interviews, or to provide study 
results/publications if requested by the participant. A list of the ID codes and the 
participant key information were kept in separate password-protected files on the 
encrypted University of Birmingham central server. No participant was referred to 
directly in the subsequent reports/publications. Only anonymised quotes were used 
within study reports/publications. Data will be stored for a period of 10 years. The 
Custodian of the data is the University of Birmingham. After this period, the data 
stored will be deleted and destroyed. 
34 
 
B. Study design 
a) Introduction 
A generic qualitative approach was used for this part of the study. A generic 
qualitative approach combines several methods or approaches and claims no 
theoretical assumptions, as compared to other qualitative approaches such as 
grounded theory, ethnography, or phenomenology [35-37].  
In some occasions, a single established methodology is insufficient or inappropriate 
to answer a research question. Therefore, drawing on the strengths of established 
methodologies by blending tools and methods provides a better way to understand a 
phenomenon [35, 36]. However, ‘method slurring’ can lead to lack of congruence. 
Researchers must make clear their assumptions and make sure the methods 
selected are aligning with their assumptions [35, 36].  Although the flexibility of 
generic studies is subject to criticism, generic qualitative approaches may identify 
new methodological approaches to support new research areas, new theoretical 
perspectives or identify new ways of evaluating previous research [36]. 
b) Justification for choice of methods 
A generic descriptive approach was deemed as the most suitable approach as it 
helped provide a straightforward and rich description of the perspectives of the 
interviewees while epitomising the qualitative characteristics of the study [35, 37]. In 
the same way, a generic approach was chosen as no theoretical assumptions were 
made. Nonetheless, this approach has been criticised for being non theory-based, 
which can lead to incongruences in the research design [35-37]. To mitigate this, it 
was clearly stated in this chapter and in the qualitative study (Chapter 5) how the 
sampling method (purposeful sampling), data collection (semi-structured interviews) 
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and analysis methods (reflexive thematic analysis) chosen were informed by the 
research question and the generic approach.  
In contrast, the absence of theory to analyse the data can be considered as strength, 
as the analysis stays close to the participants’ perceptions. However, the analysis 
will depend on the perceptions and inclinations of the researcher. To mitigate this, 
the researcher’s position was clearly stated and a multidisciplinary team including 
methodologists, clinical and non-clinical experts were involved in the interpretation 
and analysis of the data [35-38]. 
C. Sampling and recruitment procedure 
a) Introduction 
Expert and snowballing purposive sampling methods were used in combination to 
answer objective D of the thesis (Chapter 5). Expert sampling, a strategy of 
purposive sampling, aims at identifying key informants who are especially 
knowledgeable about a topic and can inform it through their knowledge, experience, 
and expertise [39]. Snowballing, friendship pyramiding or chain sampling is also one 
of the sampling methods within purposive sampling [40]. Snowballing involves 
recruiting participants through other participants [32]. Snowballing creates a chain of 
interviews based on the researcher asking each participant for suggestions about 
people who have a similar or different perspective about the information being 
sought, allowing to interview hard-to-reach groups [40, 41]. The “snowball” gathers 
pace as referrals multiply at each stage.  
The researcher continually monitors the recruitment process, which it is sustained 
until saturation is reached [40]. Saturation is defined as ‘data adequacy’, the point 
when the data collected does not provide additional information pertinent to the 
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developing analytic coding framework (i.e. when nothing new is being added) [42, 
43]. The purpose of data saturation is ensuring data replication or redundancy, 
resulting in a comprehensive and complete theoretical model [42]. Data saturation 
stresses the importance of ‘rich’ data collection and analysis rather than the quantity 
or the number of times an aspect of the phenomenon is discussed by the 
participants [42]. 
b) Justification for choice of methods 
The selection of expert sampling gave the opportunity to gain valuable insight of the 
core problems and potential solutions from key informants. In addition, some 
members of the research team (MC/DK/AS) already had established collaborative 
relationship with a range of international stakeholders and links with leading 
academic and industry trialists, journal editors, clinicians, funders and policy-makers 
and regulators, which facilitated the access to these PRO expert groups. 
Initially, the stakeholders known to the research team were approached and some of 
them were interviewed; however, 17 participants decided not to take part in the study 
for different reasons. Therefore, those participants who were interviewed were asked 
if they knew other people who would be interested in being interviewed. Snowball 
sampling was undertaken as it allowed recruitment of a further representative and 
diverse sample size in a short period of time, whilst not incurring cost. Nonetheless, 
snowballing sampling can introduce selection bias as the sample might include an 
over representation of a subgroup of participants with similar characteristics. To 
avoid over representation of participants, careful consideration was given to the 
number of participants selected per stakeholder group. In addition, a sampling frame 
was used and purposively sampled to gain a maximum variation sample. A limitation 
of the recruitment process was that the international stakeholders known to the team 
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may already be PRO advocates, which could have limited the opportunity to explore 
different perspectives about the importance and impact of PRO data. However, it 
was felt that if they were already considering ways to maximise impact and as such 
were best placed to help the research team understand and explore these impacts in 
future research. 
c) Alternative methods 
Convenience sampling was considered as an alternative approach to recruit 
participants for the qualitative project. Convenience sampling is the most common 
sampling strategy in qualitative research [40]. It is characterised for selecting a 
sample based on how accessible and convenient it is to the researcher [40]. The 
recruitment method is through the selection of a number of participants who respond 
to an advertisement, making this strategy cost efficient and time saving [32, 40]. This 
method was deemed unsuitable as the research team already had contact with 
relevant international stakeholders, who could further refer additional eligible 
participants. In addition, convenience sample is neither purposeful nor strategic, 
which can lead to incomplete data as the accessible and convenient participants are 
likely not to be the most informative sources [44].  
D. Data collection 
a) Introduction 
Semi-structured interviews were chosen to support an in-depth exploration of the 
participants’ views and experiences. This type of interview consists of asking 
participants open-ended questions to explore a topic, from which the researcher or 
participants may slightly diverge in order to explore an idea in more detail [45]. The 
interview schedule was informed by the systematic review conducted in Chapter 4, 
which was subsequently refined by two pilot interviews and discussion with the 
38 
 
research team (CM/DK/AS/MC). In addition, the interview schedule developed 
iteratively as data collection progressed in parallel to initial analysis. 
b) Justification for choice of methods 
Semi-structured interviews were deemed suitable to explore the views and 
perceptions of stakeholders, as they enable further discussion and clarification of 
answers. One of the main strengths of qualitative semi-structured interviews is that 
they allow the participants to raise issues that the researcher did not anticipate, even 
if the interview schedule was informed by previous literature, and therefore collect 
‘rich’ and detailed data about the participants’ experiences [32]. On the other hand, 
semi-structured interviews can be time consuming and costly for researchers to 
organise, conduct and transcribe. Semi-structured interviews  lack anonymity as they 
tend to be conducted face-to-face, which could be a barrier for potential participants 
and affect the recruitment process and the make-up of the sample [32]. To mitigate 
these limitations, participants were informed before accepting the interview invitation 
of the approximate length of the interview (approximately 45 minutes) and they were 
asked to choose the most convenient time and location to carry out the interview.  
c) Alternative methods 
An alternative method considered to collect data from participant was the use of 
focus groups, which are useful for exploring how different participants’ beliefs, 
concerns, experiences and opinions are around a particular topic [31]. In addition, 
the data are generated as the participants interact between themselves, which is the 
data in and of itself. Enabling the researcher to gain a larger amount of data in a 
shorter period, compared to semi-structured interviews [46]. Nonetheless, focus 
groups can be difficult to organise and the data could be influenced by a dominant 
participant (skewed data). This method would have been ideal to make comparison 
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between stakeholder groups; however, this was not possible given the nature of the 
study sample. It would not have been possible to arrange a focus group as it would 
have be difficult to find a suitable time and place because of the different time zones, 
locations and busy schedules of the participants. Although remote focus groups were 
an option, it was felt that, for practical and technological reasons, it might be too 
much of a burden for the participants. 
E. Data analysis 
a) Introduction 
Reflexive or organic thematic analysis aims to analyse, identify and report patterns 
(themes) of meaning across a dataset in relation to a research question [32, 47]. 
Reflexive thematic analysis offers flexibility around theoretical orientation and data 
collection, which allows the researcher to be actively engaged in the data analysis. 
The flexibility of this approach allows the code to constantly evolve by renaming, 
changing and collapsing codes [47]. Furthermore, reflexive thematic analysis offers a 
more accessible form of analysis, specifically for those who are new to qualitative 
research [32, 47, 48]. According to Braun and Clarke (2006), the six stages to 




Familiarisation with data set (interview transcripts) by 
‘repeated reading’ of the data and searching for meaning 
and patterns. 
II. Generating initial 
codes 
Production of initial codes from the data. Codes identify a 
characteristic of the data and refer to the most basic 
element of the data set that can be assessed in a 
meaningful way. Coding can be done manually or through 
a software programme (QSR NVivo). 
III. Searching for 
themes  
Organisation of the different codes into potential themes 
and consideration of how different codes may combine to 
40 
 
form an overarching theme (sub-theme).  
IV. Reviewing themes 
Review and refinement of the themes developed at two 
different levels. Level one, review the coded data extracts 
from a coherent pattern. Level two, consider the validity 
of the individual themes in relation to the data set and 
consider whether the themes reflect the meaning of the 
data in full. 
V. Defining and 
naming themes 
Identification of the bottom line of each theme and 
determine what aspects of the data each theme captures. 
VI. Writing themes 
Refers to the final analysis of the themes and write up of 
the thematic analysis.  
 
b) Justification for choice of methods 
Reflexive thematic analysis was chosen as it aligns with the principles set by the 
qualitative generic approach. This form of qualitative data analysis does not require 
exhaustive and technical knowledge compared to other approaches, making 
thematic analysis an uncomplicated and easy approach for new qualitative 
researchers [48]. Moreover, the ‘flexible’ element of reflexive thematic analysis 
allowed the team to use a hybrid deductive-inductive approach based on the 
aforementioned methodological framework ‘pathways to research impact’ (Chapter 
3) [25] to identify types of impact, impact measurement metrics, and barriers and 
facilitators to impact. See Chapter 5 pages 88-89 for more detail around deductive 
and inductive coding.  
In order to explore the perspectives of the international PRO stakeholders (objective 
E) it was necessary to conduct an in-depth analysis through a flexible method that 
allowed the conceptualisation of the data to evolve and develop constantly. Thus, 
reflexive thematic analysis was chosen as it allowed the researcher to actively 
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engage and interpret the data, leading to an in-depth analysis of the PRO 
international stakeholders perspectives.  
c) Alternative methods 
Two alternative approaches of thematic analysis were considered to analyse the 
dataset. These were coding reliability and codebook thematic analysis and are 
described below: 
Coding reliability approach is characterised for conceptualising themes through a 
pre-conceptualised codebook. The themes drive the coding process and are also the 
output of the coding process. Therefore, this type of thematic analysis is known as a 
‘partially’ qualitative approach to thematic analysis [47]. The underlying logic of the 
approach is positivist, which focuses on the importance of reliable and replicable 
coding (e.g. coding reliability measures) [49]. Therefore, coding reliability would have 
not allowed a deep engagement of the researcher into the data as coding reliability is 
a rigid approach, which would not have led to a rich analysis of the dataset.  
Codebook thematic analysis is characterised for determining the themes in advance 
of full analysis, and themes are conceptualised as domain summaries. Furthermore, 
the themes can evolve and be developed through the coding process [47]. This type 
of thematic analysis sits between coding reliability and reflexive thematic approach, 
as it follows a structured approach from coding reliability, except from the coding 
reliability measures, and the flexible approach of reflexive thematic analysis. 
Codebook thematic analysis includes framework analysis [50] and template analysis 
[51]. However, determining themes in advances does not allow depth of engagement 
of the research, which could lead to a thin analysis of the dataset. 
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In summary, this chapter presented a general overview of the methods chosen to 
answer the five objectives of this doctoral research. The following chapters will 
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Assessing the impact of healthcare research 
Measuring the impact of healthcare research is an essential exercise to allocate 
limited resources, demonstrate accountability and minimise research waste [1-3]. As 
described in Chapter 1, there is a lack of consensus around the most effective 
methodological framework and impact metrics to measure the impact of research. 
Therefore, the aims of this chapter were: i) identify existing methodological 
frameworks used to measure healthcare research impact and ii) summarise common 
themes and metrics to measure such impact. This chapter addresses thesis 
objective A: to identify impact frameworks and metrics aimed at measuring and 
maximising the impact of healthcare research. This chapter has been published in 
PLOS Medicine [4] (published August 9, 2017; 28,461 views, Altmetric 300 and 15 
citations to date) and is presented below in the journal format.  
 
Publication 1: 
Cruz Rivera S, Kyte DG, Aiyegbusi OL, Keeley TJ, Calvert MJ. Assessing the 
impact of healthcare research: A systematic review of methodological frameworks. 
PLoS Medicine. 2017;14(8):e1002370. (doi.org/10.1371/journal.pmed.1002370) 
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Determining the impact of PRO trial data  
Patient reported outcomes (PROs) are self-completed questionnaires that ask 
patients about the impact of a disease or treatment on their health, quality of life and 
symptoms [1, 2]. These questionnaires provide a way of measuring patients’ views 
about their health and wellbeing [2]. PRO data from clinical trials may potentially lead 
to impact for patients and society. Identifying and measuring the impact of PRO trial 
data is critical to inform funding allocation and demonstrate accountability to 
government, stakeholders and society, as discussed in Chapters 1 and 3.  
The systematic review reported in this chapter addressed the thesis objective B: to 
determine the range of potential impacts of PRO data collected from clinical trials, 
objective C: to identify potential PRO impact metrics and determine common 
barriers and facilitators to maximising PRO impact and objective D: to assess 
Research Excellence Framework (REF) impact case studies to explore real-world 
evidence of PRO trial impact and highlight optimal pathways to such impact. Further 
information on the methods used in this study can be found in Chapter 2. 
 
Publication 2: 
Rivera SC, Kyte DG, Aiyegbusi OL, Slade AL, McMullan C, Calvert MJ. The impact 
of patient-reported outcome (PRO) data from clinical trials: a systematic 
review and critical analysis. Health Qual Life Outcomes. 2019;17(1):156. 
Published 2019 Oct 16.(10.1186/s12955-019-1220-z) 
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The impact of PRO trial data: perspectives from international stakeholders 
The findings of Chapter 4 suggested that patient-reported outcome (PRO) trial data 
have the potential to inform clinical practice, clinical guidelines, health policy; support 
drug and pricing decisions and; inform clinical and shared decision-making and 
consent for treatment. In addition, examination of REF 2014 case studies appeared 
to demonstrate that a range of impact can be associated with PRO trial data, e.g. 
changes to international and national guidelines; influencing cost-effectiveness and 
drug approval. The findings of Chapter 4 also highlighted methodological problems 
regarding PRO trial design, conduct, analysis and reporting, may impair realisation of 
potential PRO impact.  
It was felt important to explore these findings further in order to gain deeper 
understanding about the identified topics. Thus, this chapter addresses objective E 
of this doctoral research thesis: to explore in-depth international stakeholders’ 
perspectives about the range of potential impacts of PRO clinical trials and impact 
metrics and; barriers and facilitators to maximise the impact of PRO trial data.  
Further information on the methods used in this study can be found in Chapter 2. 
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Background Patient-reported outcomes (PROs) are increasingly collected in clinical 
trials as they provide unique information on the physical, functional and 
psychological impact of a treatment from the patient’s perspective. Recent research 
suggests that PRO trial data have the potential to inform shared decision-making, 
support pharmaceutical labelling claims and influence healthcare policy and practice. 
However, there remains limited evidence regarding the actual impact associated with 
PRO trial data and how to maximise PRO impact to benefit patients and society. 
Thus, our objective was to qualitatively explore international stakeholders’ 
perspectives surrounding: a) the impact of PRO trial data, b) impact measurement 
metrics, and c) barriers and facilitators to effectively maximise the impact of PRO 
trial data upon patients and society. 
Methods Informed by a generic qualitative approach, we undertook semi-structured 
interviews with 24 international stakeholders between May and October 2018. 
Interviews were audio recorded and transcribed verbatim. Data were coded and 
analysed using reflexive thematic analysis. 
Findings International stakeholders emphasised the impact of PRO trial data to 
benefit patients and society. Influence on policy-impact, including changes to clinical 
healthcare practice and guidelines, drug approval and promotional labelling claims 
were common types of PRO impact reported by interviewees. Interviewees 
suggested impact measurement metrics including: number of pharmaceutical 
labelling claims and interviews with healthcare practitioners to determine whether 
PRO data were incorporated in clinical decision-making. Key facilitators to PRO 
impact highlighted by stakeholders included: standardisation of PRO tools; 
consideration of health utilities when selecting PRO measures; adequate funding to 
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support PRO research; improved reporting and dissemination of PRO trial data by 
key opinion leaders and patients; and development of legal enforcement of the 
collection of PRO data. 
Conclusion Determining the impact of PRO trial data is essential to better allocate 
funds, minimise research waste and to help maximise the impact of these data for 
patients and society. However, measuring the impact of PRO trial data through 
metrics is a challenging task, as current measures do not capture the total impact of 
PRO research. Broader international multi-stakeholder engagement and 
collaboration is needed to standardise PRO assessment and maximise the impact of 





Patient-reported outcomes (PROs) are questionnaires that capture patients’ 
perspectives about the impact of disease and treatment on their health status, for 
example quality of life and symptoms, without the interpretation of a clinician, or 
anyone else [1, 2]. Inclusion of PROs in clinical trials can provide unique patient-
centred data, which can be used to help clinicians and patients to make more 
informed treatment decisions, support pharmaceutical labelling claims and influence 
healthcare policy [3-6]. However, the lack of scientifically rigorous PRO data 
collection, analysis and reporting is a waste of resources and hinders the 
maximisation of PRO trial impact [6-9]. 
Our recent systematic review (Chapter 4) suggested that PRO trial data have the 
potential to lead to a range of benefits for patients and society, which can be 
measured through impact metrics. To date, however, there has been little research 
exploring how PRO research impact is realised and measured in practice or the 
barriers and facilitators to realising this impact. Therefore, the purpose of this study 
was to qualitatively explore international stakeholders’ perspectives on: a) the impact 
of PRO trial data, b) PRO impact metrics to measure such impact, and c) barriers 




A generic qualitative approach was chosen as it best suited to explore in-depth 
participants’ perspectives, which facilitated a rich description of their perspectives 
while staying close to the data. In addition, this approached was deemed suitable as 
no theoretical assumption were made [10, 11]. In order to obtain a broad insight of 
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the participants the following sampling, data collection and analysis methods were 
chosen, which were informed by the generic approach. In order to obtain a broad 
insight of the participants the expert purposeful sampling method was selected [12]. 
One-to-one semi-structured interviews were chosen as this qualitative data collection 
method allows obtaining ‘rich’ data by building a trust relationship with the 
participants [13]. Finally, the data was analysed using the reflexive thematic analysis 
method [14-16].  This qualitative study is reported in accordance with the 
Consolidated criteria for reporting qualitative research (COREQ) [17]. 
Sampling and recruitment  
International stakeholders over the age of 18 years, who spoke English and were 
willing and able to give informed consent were invited via email to take part in the 
qualitative interviews. Stakeholders included: policy-makers, representatives from 
regulatory agencies, funders, journal editors, academic trialists, clinicians and 
industry trialists. Individuals were eligible for interview if: a) they reported experience 
of using PRO data to inform clinical practice, clinical guidelines and health policy 
development; to support drug approval, pricing and reimbursement decisions, or to 
inform clinical decision-making and consent for treatment; or b) they reported 
experience of reviewing the PRO components of clinical trials and/or scientific 
publications. Initial recruitment approaches were made through personal research 
networks known to the team (MC/DK/AS) and  through the identification of key 
authors from relevant PRO literature (expert purposive sampling [18]); further 
participants were identified and recruited through snowball sampling [19].  
Data collection 
Semi-structured interviews were conducted by SCR between May and October 
2018, either by phone or face to face on University premises [20]. SCR, the 
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interviewer, is a doctoral researcher at the Centre for Patient Reported Outcomes 
Research within the University of Birmingham, UK. Ethical approval for this study 
was gained from the University of Birmingham (ERN_16-0806).  
All participants gave informed consent prior to each interview. An interview schedule 
(Appendix 1) was used to guide the discussion. This was initially informed by our 
systematic review on PRO trial impact (Chapter 4) and subsequently refined after 
two pilot interviews with two international stakeholders and consultation with the 
research team (CM/DK/AS/MC). The aim of the pilot interviews was to identify any 
flaws or limitations within the interview design. As no major changes to the interview 
schedule were required, these data were included in the cohort of interviews 





Table 1. Summary of interview schedule  
Topic area Summary of subtopics covered  
a) The impact of PRO trial 
results 
Exploration of international stakeholders’ 
perceptions of PRO trial impact, specifically: 
 Impact of PRO trial data on stakeholder’s 
practice 
 Thoughts, opinions and experience of 
incorporating PRO trial data in practice  
 Examples of PRO clinical trials that have led 
to impact 
 Examples of PRO clinical trials that have not 
led to impact 
b) Impact measurement 
metrics 
Exploration of stakeholders’ perceptions of the most 
effective ways to identify trials that have led to PRO 
impact, specifically: 
 Identify impact measurement metrics 
 Identify the most effective way to measure 
PRO trial impact 
 Thoughts and opinion of developing a 
framework to measure PRO trial data 
c) Perceived barriers and 
facilitators to 
effectively maximise 
the impact of PRO trial 
data upon patients and 
society 
Exploration of stakeholders’ perceptions of barriers 
and facilitators to maximise the impact of PRO trial 
data, specifically: 
 Thoughts, opinions and experience of 
facilitators to that maximise the impact of 
PRO trial data 
 Thoughts, opinions and experience of 
barriers to that maximise the impact of PRO 
trial data 
 
After the piloting exercise, data collection and analysis were conducted iteratively 
(i.e. themes identified within early interviews and interpreted within transcripts were 
included in subsequent interviews) until analytic saturation was reached. Saturation 
is defined as ‘data adequacy’ [21], the point when data collection does not contribute 
any additional information and the data collected provides comprehensive 
information to answer the research question [21-23]. For the purpose of this study, 
saturation was reached when no new themes were interpreted from the data [22, 
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23]. In this qualitative study, saturation was determined at the stakeholder cohort 
level through review of the data and discussion within the research team.  
Data analysis 
Interviews were digitally recorded and transcribed verbatim by a professional 
transcription company. Interview data were managed using a qualitative data 
analysis software package (QSR NVivo 11). Data analysis was informed by the 
reflexive thematic analysis approach [16]. In order to support the analysis and 
interpretation of the data, a multidisciplinary team including methodologists, clinical 
and non-clinical experts was involved. The analysis process started with reading the 
transcripts several times to increase familiarity with the data. This was followed by 
deductive and then inductive coding processes.  
Deductive analysis  
Initially, deductive coding was undertaken using the ‘pathways to research impact’ 
framework [24], developed as part of chapter 3, in order to identify types of PRO trial 
impact and impact measurement metrics. The framework provided a comprehensive 
summary of impact categories, impact subgroups and impact metrics across five 
types of impact: 1) Primary research related impact; 2) Influence on decision-making; 
3) Health and health systems impact; 4) Health-related and societal impact, and 5) 
Broader economic impact [24] (Appendix 2). The five impact categories of the 
framework were deductively applied to the data. In instances where it was not 
possible to categorise data into the existing framework, they were added to a 
‘miscellaneous’ coding category. Subsequently, the data coded into each of the 





More detailed codes were described and interpreted inductively within each of the 
five categories and the ‘miscellaneous’ category. In addition, inductive coding was 
also used to identify impact metrics, and barriers and facilitators to PRO trial impact, 
across the whole dataset. After the coding process, and collation of codes, theme 
generation continued until the definitive overarching themes were developed [14, 









                                                          
1
 Code: Refers to the most basic element of the dataset that can be assessed in a meaningful way. 
2 
Category: Grouping of patterns observed in the coded data in order to start the process of classifying 
findings. 
3
 Theme: Refers to characteristics of participants’ accounts describing particular perceptions relevant 
to the research question. 
4
 Main topic: Refers to the four main objectives this qualitative study focused on: types of impact, 










“I think its empowering 
patients and the public 
to understand what’s 
important to them. So 
they can go back to 
their healthcare 
provider, you know, 
take the example of 
that patient who is 
having treatment for 
breast cancer will feel 




















“The key things that 
would help 
dissemination which we 
don’t make enough of 
are patients getting up 
at conferences and 
talking about the 
change it has made to 














“Like I said, we tried to 
put PRO results in the 
primary manuscript but 
usually, in most, I get 
two or three sentences 
and that’s it. Then we 
always try to do a full 
manuscript but 
sometimes it can be 
very challenging to get 
those full manuscripts 
out there.”  
Lack of detail 
of PRO data 
in the main 
manuscript 
PRO data not 
included or lack 
of detail within 








Following inductive coding, the transcripts were again read several times to ensure 
there were no elements of the dataset missing. During the coding stage, a random 
sample of interviews (10%, n=3) was additionally coded by an independent 
researcher (CM) in order to enhance credibility of the analysis of the data collected 
(analyst triangulation) [19].  
After the coding process, data were organised and analysed following descriptive 
accounts by type of impact, impact metrics and barriers and facilitators to impact 
[25]. Subsequently, under each code a record of the meaning of the quotes was 
included. These notes helped grouping together descriptive codes that shared 
common meaning into categories in order to get a broader sense of the data. The 
final stage was to group relevant categories into themes to represent broader 
concepts of the data. The themes identified were either rearranged to create a new 
theme or collapsed to form a single theme [14]. In addition, the themes were revised 
to ensure they clearly and concisely described the dataset. Quotes that highlighted 
the nature of each theme were chosen to demonstrate prevalence. To present 
commonalities and differences among stakeholders, descriptive tables were created 
per theme and subsequently grouped by main topic. The tables included quotes that 
helped describe the key findings from the dataset. The respective coding, categories 
and themes decisions were discussed with the research team (DK/AS/MC) to inform 
the final analysis and interpretation of the data.  
Results 
Of 41 stakeholders invited to participate, 24 semi-structured interviews were 
conducted with a range of international stakeholders. Reasons for declining 
participated included lack of availability (n=4), preference to maintain a neutral 
position regarding the topic (n=1), belief they were ineligible (n=1). In addition, 11 
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people did not respond to the invitation. Interviews lasted on average 35 minutes 
(range 24 to 55 minutes). Most of the interviews (n=21) were conducted by phone 
whilst three took place face-to-face on University premises. Interviewees self-
identified with a range of stakeholder groups including academic and industrial 
trialists, journal editors, clinicians, funders and policy-makers/regulators. Six 
participants identified with more than one group. Participant summary characteristics 




Table 3. Participants’ characteristics 
Stakeholder 
group 





USA University 1 
Australia University 2 
The Netherlands University 3 
Canada University 9 
USA University 10 
Industry 
trialists 
USA Research institute 4 




























USA University 1* 
UK Government 8* 
Canada University 9* 
UK Charity 18* 
USA Funding institute 19* 
UK University 23 
UK University 24* 
Policy-makers 
and regulators 
USA Regulatory agency 6 
UK Regulatory agency 8 
Germany Reimbursement agency 12 
UK Regulatory agency 13 
UK Reimbursement agency 14 
Funders UK Charity 18 
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USA Funding institute 19 
UK Government 20 
USA Funding institute 21 
USA Funding institute 22 
*Participant included in two different stakeholder groups. 
Interpretation of four core themes are presented in this section: 1) types of PRO 
impact 2) PRO impact metrics and 3) barriers to PRO trial impact, and 4) facilitators 
to PRO trial impact. To explain the dataset in a meaningful way, an informed 
approach was adopted. The dataset was presented against these four core themes, 
which relate back to the five types of impact categories as appropriate throughout. 
 Results are presented below with quotes labelled as shown in Table 4 followed by 
participant number. Deviant cases were explored and presented were appropriate. 
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1. Types of PRO impact  
The following section describes the different types of impact identified by 
stakeholders in which PRO trial data were purported to have an impact.  
1.1  Primary research related impact 
This is an impact associated with the generation of new knowledge, dissemination of 
results, building of research capacity, delivery of training and development of new 
leadership, and academic collaborations and networks. This impact is expected to be 
generated in the short-term, one year or less [24].  
Academic and industry trialists, clinicians and funders were the main stakeholder 
groups that discussed the potential impact of PRO trial findings on ‘research and 
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innovation outcomes’. They believed that publications (including press releases and 
lay summaries), peer reviewed articles and citation rates have the potential to 
maximise the impact of PRO trial data outcomes by making the PRO data available 
to patients, clinicians and decision-makers. Another type of PRO impact mentioned 
was ‘dissemination and knowledge transfer’, which participants identified as 
presentation of PRO trial data in conferences by leaders or experts (including 
patients), mass media, and translation of PRO data to other research areas.  
“The most impactful thing is when a respected expert gets up on the podium 
and says, “It’s really important that this study showed pain improvements and 
we should be telling our patients that their pain gets better.” That makes a big 
difference […]” CL1 
















Table 5. Primary research related impact quotes
Types of impact 
Discussed by 





































Publications       “[…] publications are there in the literature to be read. So, I think 
those are important, and in publication in high ranking journals 








      
“It needs someone like NCRI or NIHR or Evolve or someone just 
to put a call out.  If you’ve had a study that’s improved something 
via PRO measures, if PROM’s have made an impact tell us what 
the study was, tell us what it is, and by the way we’re looking to 
do a showcase for you to talk about it at this or that conference 




      
Mass media       
“It could also be TV, radio; newspaper advertisements and other 
form of media are also ways to spread the knowledge about the 
PRO’s and to advance the matter so that different people with 
little understanding of statistics and epidemiology can 
understand.” IT16 
Translation of 
PRO data to 
other research 
areas 
      
“It can also be that it will be translated, or that it will be applied in 
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1.2  Influence on policy-making 
This type of impact refers to the interaction between policy-makers and academics 
and available knowledge base, which may result in changes to policy. These impacts 
are generally considered to arise in the mid-term (1 to 3 years) [24].  
Several interviewees highlighted the potential impact of PRO trial data on ‘type and 
nature of policy-making’, by influencing changes clinical guidelines to practice and 
providing information to support drug approval, pharmaceutical labelling claims and 
promotional labelling claims.  
“[…] to support a drug license, what we would hope in the future is that patient 
reported outcomes are the patient voices captured in a way, in a robust way, 
and an objective way that would allow that data to be integrated into the 
assessment of benefits and risks and then concluding on whether a drug 
should be given a drug license” PM-RE13 
 
For instance, some clinicians stated that PRO trial data had influenced their own 
practice by informing nuanced conversations with patients and supporting careful 
selection of treatments and giving them confidence to choose the best healthcare 
treatment while considering toxicity and side effects.  
“So, for treatments that I discuss with patients, when there are results from 
trials with information about patient reported outcomes, specifically about 
symptoms or physical functioning, or overall quality of life I include those in 
my discussion with patients when they’re making a decision about a 
treatment.” CL1 
The impact subgroup ‘type and nature of policy-making’ was mainly discussed by 
academic trialists, policy-makers and regulators. See Table 6 for further quotes on 
influence and policy-making impact. 
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Table 6. Influence on policy-making impact quotes  
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      
“So there was a study where, if you like, the 
cancer control outcomes were the same but 
the PROM’s were improved with radiotherapy. 
That’s a trial that’s influenced my practice and 
makes me feel very confident to offer 
radiotherapy in preference to surgery for those 















































      
“When Mitoxantrone was approved in 1996, I 
think around that time anyway, I mean yes, 
guidelines for treatment of metastatic prostate 
cancer changed to include Mitoxantrone as a 
treatment, a recommended treatment for 
patients who develop hormone resistant 
prostate cancer.” CL9 
Drug 
approval* 
      
“So when we’re weighing up the efficacy data 
and the safety data, to support a drug license, 
what we would hope in the future is that 
patient reported outcomes are the patient 
voices captured in a way, in a robust way, and 
an objective way that would allow that data to 
be integrated into the assessment of benefits 
and risks and then concluding on whether a 




      
“In the case of Abiratone Acetate, it was such 
an important endpoint that it’s included in the 





      
“Of the labelling and so that’s going to be 
different by country because in the US we 
have direct consumer advertising, so PRO 
messaging can go right to the patient, and 
then patient might go to the doctor and say ‘I 
saw this commercial and it says I would have 
improved physical function if I take this 








1.3  Health and health systems impact 
Health and health systems impact encompasses the benefits of health research 
outputs on `quality of care and service delivering', ‘evidence-based practice', 
‘improved information and health information management', ‘cost containment and 
effectiveness', ‘resource allocation', and ‘health workforce'.  This type of impact is 
expected to arise in the long-term, beyond five years [24]. 
Clinicians and funders were the only stakeholder groups who highlighted the impact 
of PRO trial data on ‘evidence-based practice’, specifically on the subgroup fulfilling 
previously unmet needs. 
“Collecting PROMs on a regular basis allowed us to demonstrate that the 
management of lymphoedema within our organisation was an unmet need, 
and using that data, we could then use that to influence purchases and 
commissioners and make that the backbone of a business case which 
allowed us to provide new services for patients with lymphoedema.” FU18   
 
The impact subgroup ‘quality of care and service delivery’ was only discussed 
among academic and industry trialists, clinicians and funders. These stakeholder 
groups emphasised the impact of PRO trial data on improved health outcomes. The 
impact subgroup ‘cost containment and effectiveness’ was predominant among all 
the stakeholder groups but journal editors. Academic and industry trialists and policy-
makers and regulators highlighted the impact of PRO trial data on cost effectiveness. 
“Well, I sub-divide patient reported outcomes into disease specific PROs and 
generic ones.  The generic ones in particular, EQ-5D.  All of the trials that 





Academic and industry trialists, clinicians, funders and policy-makers and regulators 
thought that PRO trial data can capture improvements in health-related quality of life 
that can be used in combination with other clinical outcomes to the contribution of 
health institutions cost savings. Furthermore, industry trialists, clinicians and funders 
mentioned that the adoption of a healthcare treatment that improves health-related 
quality of life could have an impact on the reduction in the number of work loss days, 
which leads to improved work productivity. The impact sub-category ‘reduction in the 
number of work loss days’ is encountered within the category ‘healthy workforce’. 
“For irritable bowel syndrome […] patients had less gas and less this and that, 
but also that led to improvement in work productivity. They went back to work 
much earlier so that sort of thing certainly has impact in certain segments of 
the market.” IT4 
 
In general, clinicians and funders primarily highlighted the impact of PRO trial data 
on the ‘health & health systems’ type of impact. Moreover, the impact category 
‘resource allocation’ was not discussed by any of the interviewees.  See Table 7 for 
further quotes on health and health systems impact. 
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Table 7.  Health and health systems impact quotes 















































      
“Collecting PROM’s on a regular basis allowed us to 
demonstrate that the management of lymphoedema 
within our organisation was an unmet need, and using 
that data, we could then use that to influence purchases 
and commissioners and make that the backbone of a 
business case which allowed us to provide new services 
for patients with lymphoedema.” FU18  






      
“We looked at enhanced recovery in people undergoing 
anterior resections of the rectum using laparoscopic 
surgery and enhanced recovery methodologies […] it 
was the fact that the patient reported outcomes in the 
subsequent weeks and months post operatively 
demonstrated a much quicker return to a high quality of 
life as opposed to open surgery.”IT4 
Patient 
satisfaction 
      
“How satisfied [patients] are but also more detailed 
appropriate patient related outcomes. […] We have to 
find qualitative systematic ways for doing that because 
what you want to achieve is the same level of 
satisfaction but the outcome for individuals could be 







      
 
Reduction in 




1.4  Health-related & societal impact  
Health-related and societal impact includes the impact subgroups: ‘health literacy’, 
health knowledge, attitudes and behaviours’ and ‘improved social equity, inclusion or 
cohesion’. This type of impact is also expected to be generated in the long-term, 
beyond five years. 
Funders and a small number of clinicians highlighted that PRO trial data can 
influence health literacy, by providing information on how patients are affected by a 
health condition. They believed that this information can be used to change the 
general perception of a disease or de-stigmatise it (e.g. cancer and mental health 
conditions) and help patients ‘live better’ with that condition. Industry trialists and 
funders considered the impact of PRO trial data on patient advocacy groups, which 
is encountered within the impact category health knowledge, attitudes and 
behaviours. These interviewees mentioned that patient advocacy groups can 
influence drug development by communicating to health authorities patients’ 
priorities. 
“I think PROs can affect the public image of the disease.  I think one of the 
things we’re all hoping for some day, are treatments for cancer that can help 
turn what, for many people is a fear of even being with somebody who has 
cancer into something more positive, that cancer becomes something that we 
treat like arthritis.” F21 
Industry trialists and funders were the only stakeholder groups that mentioned the 
potential impact of PRO trial data on ‘health-related & societal impact’. Furthermore, 
the impact category ‘improved social equity, inclusion or cohesion’ was not 




Table 8. Health-related and societal impact quotes









































      
“A field can be changed in terms of the way in which 
the impact of the condition is on an individual or on a 
population or on a health system is conceptualised 
and patient reported measures can have a huge role 
to play in that […] I think there’s good examples in 
urinary incontinence therapeutic area that some of the 
measures that have been developed have changed 















      
“the efforts being made to translate clinical trial 
outcomes by patient advocacy groups in terms that a 
patient can understand.  So when they go to their 
clinician they ask for this information or if they know 




1.5  Broader economic impacts 
This impact category refers to the generation of economic revenue generated from 
the commercialisation of health research output. This type of impact is also expected 
to arise in the long term. Industry trialists suggested that PRO trial data can 
contribute to increasing pharmaceutical companies’ sales and revenue. By using 
PRO trial data to attract income from intellectual property and increased 
pharmaceutical sales. 
“Think in the pharmaceutical industry, because we’re selling products, one of 
the main ways they evaluate whether or not it’s a success is how much it 
sells, how frequently it’s used and whether or not it becomes part of 
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 Human rights 
 Patient advocacy 
groups 
Figure 1. Pathways to PRO trial impact 
Short-term       Mid-term       Long-term         




2. Impact measurement metrics 
Interviewees proposed different quantitative and qualitative metrics to measure the 
impact of PRO trial data. These included: the number of citations of PRO 
publications; journal impact factor; and how often a PRO endpoint was presented in 
blogs, online communities and social media.  
“How many times the article on the PRO’s has been cited. That’s one 
measure. The standard metrics that the journals and articles have regarding 
impact.” IT16 
Additional impact metrics proposed included: number of clinical trials conducted 
which included PROs as an endpoint and number of labelling claims. Evaluation of 
health technology assessment documentation to determine whether PRO data 
inform drug approval. Surveys and interviews among healthcare practitioners and 
patients to determine whether PRO data are incorporated into clinical decision-
making or used to inform patient shared decision-making.  
“I think there are experimental methods that could be applied, so sampling, 
[…] there’s quantitative survey methods that could be used, but also 
qualitative methods to be sure to be capturing what it’s impact is, for instance, 
how information from a PRO affected thinking and behaviour on the part of 
the end user.  By end user I mean an individual with a condition or a clinician 
and even to the level of the health system.” FU21 
In contrast, several stakeholders highlighted that measuring PRO trial data through 
metrics is a challenging task and it might not accurately represent the real impact of 
PRO trial data. 
3. Barriers to PRO impact 
Interviewees highlighted a range of perceived barriers that they felt may impair the 
realisation of impact arising from PRO trial findings, including: 1) poor quality trial 
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design, 2) suboptimal conduct and analysis, 3) poor reporting quality, and 4) 
dissemination and uptake of PRO results.  
3.1  Poor quality trial design 
Poor quality trial design refers to the lack of PRO-specific methodological rigor 
during the design stage of the clinical trial, which limits the realisation of PRO trial 
impact in the subsequent stages of the clinical trial. All stakeholder groups, with the 
exception of industry trialists and funders, mentioned poor quality design as one of 
the barriers to PRO impact. Interviewees highlighted PRO trial barriers such as lack 
of detailed PRO protocol and lack of adherence to it. 
“[PROs are] either exploratory endpoints that are either added in 
inappropriately, the timings are incorrect, the instrument might not be correct 
for the particular patient population, the analysis hasn’t been thought through, 
there’s no hypothesis or objectives listed in the study protocol.” PM-RE13 
 
Further barriers identified were the inclusion of PROs in the clinical trial as 
secondary outcome, lack of PRO trial information from phase I and II limiting the 
design of the PRO component in phase III and; late or not incorporation of PRO 
experts in the development of the clinical trial protocol.  
 
"[…] we would get sent the protocol right at the end, right before the trial was 
going to be sent to ethics or sometimes even after they had received ethical 
approval. We would make suggestions to improve the protocol with respect to 
PRO’s and then some of the investigators would be reluctant to make those 
changes because it meant they would have to do an extensive protocol 
amendment" AT2 
See Table 9 for further quotes on poor quality trial design. 
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Lack of detailed PRO 
protocol 
      “[PROs are] either exploratory endpoints that are either 
added in inappropriately, the timings are incorrect, the 
instrument might not be correct for the particular patient 
population, the analysis hasn’t been thought through, 
there’s no hypothesis or objectives listed in the study 
protocol.” PM-RE13 
Lack of adherence to 
PRO protocol 
      
Inclusion of PRO data 
as secondary endpoint 
      
“[…] We don’t see very good advanced planning to use 
PRO in the drug development process; […] patients 
reported outcome measures are only classed as 
exploratory endpoints […] then their impact to regulatory 
decision-making can only be very limited.” PM-RE13 
Lack of PRO 
information from phase 
I and II trials limits the 
design of the PRO 
component in phase III 
trials 
      "[…] we would get sent the protocol right at the end, right 
before the trial was going to be sent to ethics or sometimes 
even after they had received ethical approval. We would 
make suggestions to improve the protocol with respect to 
PRO’s and then some of the investigators would be 
reluctant to make those changes because it meant they 
would have to do any extensive protocol amendment" AT2 
Late or not 
incorporation of PRO 
experts in the trial 
protocol stage 
      
87 
 
3.2  Suboptimal conduct and analysis 
The way the trial was conducted and the type of analysis that is implemented were 
mentioned as barriers to maximise the impact of PRO trial data. Suboptimal conduct 
and analysis was a predominant theme among all the stakeholders; however, it was 
discussed to a lesser degree by journal editors and clinicians. This theme included 
barriers related to high rates of missing data, difficulty collecting PRO data among 
global trials, patient and staff burden and lack of training for clinicians to optimally 
conduct a PRO clinical trial and analyse PRO trial data and; lack of expert reviewers 
to assess PRO trial results. 
"Medical journals often lack sufficient experts who can review PRO results 
because the researchers and clinicians who are journal reviewers are not 
knowledgeable about PRO[s]." IT11 
An additional barrier identified surrounded a perceived lack of understanding and 
interpretation of PRO data by clinicians, patients and patient advocates.  
“PRO experts, sometimes assume that the clinicians will understand tables 
and figures and the interpretation of the clinical trial and I think we know from 
experience that clinicians don’t always get the message.” IT17 
See Table 10 for further quotes on suboptimal conduct and analysis.  
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High rates of missing 
PRO data 
      "So if there is a high number of missing values, then the impact is very intensively lowered […]" PM-RE12 
Difficulty collecting 
PRO data among 
global trials 
      
“Global trials that involve many countries and languages 
raise special challenges for PRO where translations are 
required and collection of PRO may be more challenging to 
get sites to collect correctly.” IT11 
Patient and staff 
burden 
      
“The burden on patients is still an issue and a barrier at 
times. I think we’ve been ineffective in trying to develop 
parsimonious PRO’s.” PM-RE6 
Lack of training for 
clinicians 
      "Physicians don’t have training in patients reported 
outcomes unless they have an interest in that area." IT4 
Lack of expert 
reviewers to assess 
PRO trial results 
      
"Medical journals often lack sufficient experts who can 
review PRO results because the researchers and clinicians 
who are journal reviewers are not knowledgeable about 
PRO." IT11 
Clinicians, patients, 
patient advocates and 
policy makers lack of 
understanding and 
interpretation of PRO 
data 
      
“PRO experts, sometimes assume that the clinicians will 
understand tables and figures and the interpretation of the 
clinical trial and I think we know from experience that 
clinicians don’t always get the message.” IT17 
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3.3  Poor reporting quality  
This theme was primarily highlighted by academic trialists. Barriers emphasised by 
interviewees included: lack of discussion of PRO outcomes; inclusion or detailed 
information within the main clinical trial publication; PRO data explanation in view of 
other clinical endpoints and; publication of PRO trial data many years after 
publishing the main trial manuscript or its lack of publication. 
“I came across a few trials where the PRO results hadn’t been published […] I 
saw that certain trials had PRO of secondary endpoint but then when I found 
the publication that related to it, that was just completely missing and 
sometimes they would say that the PRO results would be published later but it 
had been several years down the track.” AT2  
Further barriers to PRO impact interpreted included publication of clinical trials 
manuscripts including PRO data in a technically correct language, but difficult to 
understand for patients, advocacy groups and patients and; restricted access to 




























Lack of discussion of 
PRO outcomes 
      
“I think not being published is a big one but also because in 
the main trial publication, if they are reported then it might 
just be very minimal information that’s not really…not that 
it’s not informative, I mean it’s good to know if there are 
differences between the groups but I think is so much more 
rich than just that.” AT2 
Lack of inclusion or 
detailed PRO 
information within 
the main trial 
publication 
      
Lack of PRO data 
explanation in view 
of other clinical 
endpoints 
      
Lack of journals 
endorsement  
      “I’m not sure that scientific papers have really got their head 
around the importance of patient reported outcomes.” FU20 
PRO trial data are 
never published or it 
is published years 
after the main trial 
publication in a low 
impact journal 
      
“I came across a few trials where the PRO results hadn’t 
been published […] I saw that certain trials had PRO of 
secondary endpoint but then when I found the publication 
that related to it, that was just completely missing and 
sometimes they would say that the PRO results would be 




























PRO publications in 
journals report PRO 
findings in a 
technically correct 
language but difficult 




      
“There is certainly information that patients want to know 
about when making a treatment decision and the difficulty is 
translating those outcomes from the trials into ways that 
clinicians can understand those outcomes.” IT17 
Restricted access to 
PRO publications 
(paywall restrictions) 
      
"If you publish it in a very scientific journal and if you are not 
based in a university, you cannot even read that paper 
because you don’t have access to those papers. How 
would you know?" AT3 
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3.4 Dissemination and uptake of PRO results  
This included PRO-specific issues faced upstream that limited the propagation and 
adoption of the findings into clinical practice. This theme was common among journal 
editors, clinicians and policy-makers and regulators, whereas academic trialists 
commented on this theme to a lesser extent. 
Barriers encompassed lack of awareness of PRO data importance between 
clinicians, researchers, journal editors and sponsors and; prioritisation of clinical 
outcomes over PRO trial data by researchers and funders. 
“The main reason is that the high impact journals want survival data and if 
they’ve got a survival advantage they don’t bother with the quality of life data. 
[…] There’s a study of a drug which has a two-month survival advantage, 
worse toxicity, quality of life data collected but not published. It’s outrageous.” 
FU19 
Additional barriers discussed were lack of engagement between academic 
researchers and research companies with patients to understand patient priorities, 
collaboration between PRO researchers within same health research areas and law 
or regulation in the UK to enforce the collection of HRQL in clinical trials. 
"So we are law enforcers if you like. Now, that doesn’t really incorporate 
PRO’s, there is no specific law if you like, that they’re going to break if they 
don’t include a PRO or include it in the wrong context or what have you. So 
it’s almost, I suppose, supplementary information. It’s not regulated in any 
way in terms of black and white text." PM-RE8 
Other barriers that reportedly might hinder the maximisation of PRO trial data were 
the limitation of PROs not automatically becoming health utilities, the different 
perspective surrounding the inclusion of PROs in clinical trials between the EMA and 
FDA and the difficulty getting funding for PRO research.  
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"One of the major funders of research in this country is very unlikely to fund research 
that has a PROM as a primary outcome. They’ve made that a strategic intent, so the 
playing field is already biased against PROM’s based research." FU18 














































Lack of awareness of 
PRO data importance 
among clinicians, 
researchers, journal 
editors and sponsors 
      
"I think there is still a challenge in the scientific community 
to see the value of patient reported outcomes as just an 
important and integral part of our understanding of medicine 




rather than PRO data 
      
“The main reason is that the high impact journals want 
survival data and if they’ve got a survival advantage they 
don’t bother with the quality of life data. […] There’s a study 
of a drug which has a two-month survival advantage, worse 
toxicity, quality of life data collected but not published. It’s 
outrageous.” FU19 




with patients to 
understand patient 
priorities 
      
“The EMA does not permit direct communication from 
pharma companies to patients, so there are significant 
challenges sharing more patient-friendly explanations of our 
PRO research in newsletters, websites, or white papers that 
could be accessed by patients or clinicians other than with 
those who participated in the trial or through the Layperson 
Summary of the trial.” IT11 
 
Lack of collaboration 
between PRO 
researchers within 
same health research 
areas 
      
"One problem is everyone tries to set up their own shop and 
so instead of trying to say, we’re going to develop a great 
tool for gastrointestinal distress, for example, you have six 
or seven groups that develop groups for very specific 














































Lack of law or 
regulation in the UK 
to enforce the 
collection of HRQL in 
clinical trials 
      
"So we are law enforcers if you like. Now, that doesn’t really 
incorporate PRO’s, there is no specific law if you like, that 
they’re going to break if they don’t include a PRO or include 
it in the wrong context or what have you. So it’s almost, I 
suppose, supplementary information. It’s not regulated in 





      
"[…] [PROs] don’t suffer from the problem of not collecting 
things that will be affected by the disease; they do suffer 
from the problem that they don’t automatically become 
utilities, although many of them can be mapped." PM-RE14   




inclusion of PROs in 
clinical trials 
      
"[…] the EMA seems to be more willing to accept scientific 
publications and information in the literature than the FDA 
is, depending on the reviewing decision, it may be easier or 
harder to get a PRO in the label, so it’s not an even playing 
field across the different divisions." IT17 
Difficulty getting 
funding for PRO 
research 
      
"One of the major funders of research in this country is very 
unlikely to fund research that has a PROM as a primary 
outcome. They’ve made that a strategic intent, so the 




4. Facilitators to PRO impact 
Interviewees highlighted a range of perceived facilitators that they felt may enhance 
the realisation of PRO trial findings including: 1) improved PRO trial design, 2) 
optimal conduct and analysis, 3) improved reporting and 4) dissemination and 
uptake of PRO results.  
4.1  Improved PRO trial design  
This theme was primarily discussed by policy-makers and regulators. It was not 
discussed among journal editors and clinicians. Improved PRO trial design 
facilitators discussed by interviewees included: the production of a clear and detailed 
PRO protocol; endorsement of the PRO data as a key endpoint in clinical trials; and 
early incorporation of a PRO expert in the trial team. 
"There should be a PRO expert on the clinical trial team and at the earliest 
possibility; if you start thinking about your PROs at the reporting stage it is far too 
late. You need to be thinking much earlier on."AT3  
Participants also discussed adherence to PRO guidelines, inclusion of patients and 
clinicians in the trial design stage, regular meetings with regulatory agencies during 
the planning period and the end of the trial and; the development of PRO measures 
while considering health utilities for HTA use. 
"The patient reported outcomes world could think of utilities at the same time 
as developing their PRO’s. So any patient reported outcome that has got a 
utility mapping attached to it is very useful." PM-RE14 
See Table 13 for further quotes on improved PRO trial design.  
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Clear and detailed 
PRO protocol 
      
"The protocol is very complete, very detailed about how to 
interpret the metrics, how to measure them and 
standardise their use and so on. The findings are more 
likely to be considered to be valid and reliable." JE7 
Endorsement of PRO 
data as key endpoint 
in clinical trials 
      
"I think that they have to be key endpoints in clinical trials 
[…] if you look at arthritis where the main endpoint is a 
symptom, people talk about symptoms more. I think that 
when you get into diseases where there are other 
endpoints, like survival, people tend to focus more on 
those." CL1 
Early incorporation 
of a PRO expert in 
the trial team 
      
"There should be a PRO expert on the clinical trial team 
and at the earliest possible, if you start thinking about 
your PROs at the reporting stage it is far too late. You 
need to be thinking much earlier on."AT3 
Adherence to PRO 
guidelines 
      
"[...] the SPIRIT PRO guidelines, the CONSORT 
guidelines, the guidelines coming out of SISAQOL and 
ISOQOL, the guidelines that have been recommended by 
the US FDA about what things should be included when 
you’re trying to measure well the patients experience." 
IT11 
Inclusion of patients 
and clinicians in the 
trial design stage 
      
"It’s really important to speak to clinicians and patients 
about what issues seem to be most troublesome for 
patients before they start treatment and then to talk about 
whether the clinician expects the therapy understudy will 


























agencies during the 
planning period and 
at the end of the trial  
      
"We give comments during the planning period so that 
there are relatively few questions at the end because we 
will reanalyse the data and go through everything at the 
end but that’s too late if there is a problem." PM-RE6 
Development of PRO 
measures while 
considering health 
utilities for HTA use 
      
"The patient reported outcomes world could think of 
utilities at the same time as developing their PRO’s. So 
any patient reported outcome that has got a utility 
mapping attached to it is very useful." PM-RE14 
99 
 
4.2 Optimal conduct and analysis 
Facilitators to achieve optimal conduct and analysis were highlighted by policy-
makers and industry trialists, whereas journal editors and clinicians did not contribute 
to this theme. Facilitators discussed were high completion rates of PRO trial, training 
sites on the administration, make PRO data more readily understandable and; 
explanation of PROs and standardisation of PRO tools among therapeutic areas to 
improve analysis. 
"Having standardised tools across trials helps us understand the trial results 
and be able to compare things more easily. [...] Certainly in the US with 
qualification process for PROs, there’s a hope that each of us will not go out 
and create one off our own tool, instead have some standardisation." IT5 







































      
"Try to collect the data from the start until the end of the 
trial. Also for patients withdrawn from treatment, and also 
from patients withdrawing from the trials, so there’s a 
possibility to get an observation from these." PM-RE12  
Training sites on the 
administration and 
explanation of PROs 
      
"So you have to train the sites and the sites have to be 
comfortable and understand the tools so they can 
appropriately explain them to patients." IT5 
Standardisation of 
PRO tools among 
therapeutic areas to 
improve analysis 
      
"Having standardised tools across trials helps us 
understand the trial results and be able to compare things 
more easily. [...] Certainly in the US with qualification 
process for PROs, there’s a hope that each of us will not 
go out and create one off our own tool, instead have some 
standardisation." IT5 
Make PRO data more 
readily 
understandable 
      
"One thing is to do a little bit of interpretation to clinicians, 
so they can look at it and they don’t have to know that a 
55 is bad.” IT17 
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4.3  Improved reporting  
Improved reporting was predominant among academic trialists and journal editors; 
however, this theme was not discussed by industry trialists, policy-makers, and 
regulators. Facilitators encompassed in this theme were open access publications 
and PRO trial data reported in the main publication and in a high impact journal.  
"The studies which have been impactful have been ones where the quality of 
life data and the survival data has been published together in a high impact 
journal" FU19 
Further facilitators comprised simple English summary of the trial results for use of 
patients, availability of more journals to publish PRO trial data and make PRO 





























      
“No paywall, it has to be available. There’s no point having 
a journal that’s accessible to patients if they have to pay 
for it." JE15 
PRO trial data 
reported in the main 
publication and in a 
high impact journal  
      
"The studies which have been impactful have been ones 
where the quality of life data and the survival data has 
been published together in a high impact journal" FU19 
Inclusion of a simple 
English summary of 
the trial results for 
use of patients   
      
"We insist on having a simple English summary of each 
paper and when authors submit to us, if the simple 
English summary isn’t clear, then we won’t read the 
paper. It goes back to the authors." JE15 
Availability of more 
journals to publish 
PRO trial data 
      
"So having more PRO clinical trial venues to publish 





      
“It is extremely important that we make tools publicly 
available […] and then sharing that information through 
publication to continue to act at the weight of evidence 
around the validity of the tool. […] sometimes the PRO 
becomes part of the company’s intellectual property.” IT5 
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4.4  Dissemination and uptake of PRO results  
Finally, dissemination and uptake of PRO results was emphasised by all the 
stakeholders but to a lesser extent by policy-makers and regulators. This theme 
highlighted facilitators such as adequate funding and the important of funders clearly 
stating their position around PROs and their expectations of the funded PRO 
research. 
“I think funders have a role because they can stipulate, for example, that the 
work they fund must have some sort of an implementation plan so that work 
isn’t just completed and then perhaps published in a journal and then never 
heard from again. Having emphasis on ensuring that there is some pull 
through into use and impact as a direct requirement of funding would go a 
long way as well to help the problems.” FU21 
In addition, it was suggested that funders should require an implementation plan in 
terms of usage and impact of the PRO clinical trial as a direct requirement of 
funding. Facilitators suggested that might enable the dissemination and uptake of 
PRO results included: provide PRO training courses for clinicians and drug 
developers and communicate PRO research widely through the involvement of key 
opinion leaders, specifically at healthcare conferences. 
"To allow organisations like the NCRI, ASCO, ESTRO, the organisations that 
host large healthcare provider conferences to make PROM’s based research 
a future of their sessions and their main talks and also to improve quality of 
science communications so that we have skilled science communicators 
disseminating these results." FU18 
Further facilitators highlighted included empowerment of patients through their 
involvement in discussions and dissemination of PRO trial results and; endorsement 
of PRO trial studies by key societies to disseminate results and influence healthcare 
policy. See appendix 3.5 for additional quotes. See Table 16 for further quotes on 
dissemination and uptake of PRO results
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Adequate funding       
“I think as a funder we have an opportunity to assert some 
leverage about the outcomes that go into the trials that are 
selected for the trials and if you want our funding then you 
have to meaningfully incorporate PRO’s into the design.  
You wouldn’t want to skip right into practice without some 
reasonable understanding about what the PRO’s can 
predict, how they can affect other treatment outcomes and 
research itself on whether patients find them meaningful.” 
FU22  
Funders should 
clearly express their 
position about PROs 
and what they expect 
from the funded PRO 
research 




in terms of usage 
and impact of the 
PRO clinical trial as a 
direct requirement of 
funding 
      
“I think funders have a role because they can stipulate, for 
example, that the work they fund must have some sort of 
an implementation plan so that work isn’t just completed 
and then perhaps published in a journal and then never 
heard from again.  Having emphasis on ensuring that 
there is some pull through into use and impact as a direct 
requirement of funding would go a long way as well to 
help the problems.” FU21 
Training courses for 
clinicians and drug 
developers 
      
“Having training courses that meet the needs of people, 
nothing too long, targeting events that are already up and 
running, like having a PRO session at a conference that’s 





















































     
 “[…] so in Brighton and Sussex we have Professor Dame 
Lesley Fallowfield who has been a champion of PROM’s 
for many years. She is often invited to conferences as a 
plenary speaker because she speaks very well about 
PROs and argues vehemently for PROs.   [...] She can 
stand up in front of ten thousand doctors at ASCO and 
say, you should be measuring PROM’s.  We need more 
key opinion leaders like that who can be charismatic and 




their involvement in 
discussions and 
dissemination of 
PRO trial results 
     
 
"Let’s have a patient standing up saying, my life is better 
because of this. It’s not just got rid of my cancer, but 
actually I can cope with life, it’s given me these things to 
cope with but actually I can cope with those." JE15 
Endorsement of PRO 
trial studies by key 
societies to 
disseminate PRO 
results and influence 
healthcare policy 
     
 "[...] like the charities, like Macmillan, like Cancer 
Research UK to be having conversations with government 
and NHS England to make sure that policy is changed. 
The biggest changes in healthcare don’t come from 





For the first time, this study provides international stakeholder perspectives on the 
types of impact associated with PRO trial results, impact measurement metrics, and 
barriers and facilitators to effectively maximise the impact of PRO trial data upon 
patients and society.  
Stakeholders identified a number of ways in which PRO data from clinical trials can 
potentially inform/influence primary research, policy-making, health and health 
systems, health-related and societal impact and broader economic impacts. 
Although every interviewee was asked similar questions, not all of them discussed 
each type of impact. It was interpreted from the data that stakeholders appeared to 
focus on the impact categories that were most relevant to them and did not focus on 
broader aspects of PRO impact, even when prompted. The dataset provided rich 
narratives when the interviewee had experience of a particular type of PRO impact. . 
For instance, academics primarily focused on ‘primary research related impact’. 
Arguably this stakeholder group might be more focused on producing research 
outcomes and their dissemination, rather than the broader benefits these outcomes 
may have on patients and society. Nonetheless, PRO stakeholders agreed on the 
benefit of including PROs in clinical trials and did consider a range of impacts. 
The majority of the stakeholders suggested that measuring the impact of PRO trial 
research can benefit academic researchers, trialists, policy-makers, regulatory 
authorities, funding bodies, pharmaceutical companies, payers and patients. 
Measuring the impact of PRO trial findings may help stakeholders understand the 
importance and value of PRO trial data, broaden their perspectives regarding PRO 
applicability, and identify the different benefits to society through improved health 
outcomes and use of resources [26]. For instance, these data would provide a 
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knowledge base to policy-makers, regulators and funders to justify drug approval 
and inform funding allocation decisions through demonstrating the potential benefits 
on patients and society [24, 27]. Moreover, journal editors and academics might be 
more likely to acknowledge the importance of PRO data and ensure timely, 
transparent publication of PRO trial data in high impact journals. Considering the 
impact of PRO trial impact, it has the potential to influence the study design and 
determine the possible benefits of conducting a particular study.  
Stakeholders proposed several qualitative and quantitative metrics to measure the 
impact of PRO research. Quantitative metrics included number of publications, 
citations including PROs as an endpoint and number of regulatory approvals 
including PROs and; surveys among stakeholders and patients to determine how 
PRO data are being used. Qualitative metrics comprised interviews among people 
involved in the drug approval process to determine whether PRO trial data inform 
drug approval appraisal. However, most interviewees highlighted that measuring the 
impact of PRO trial research is a challenging task as it cannot be captured 
systematically. Single cross-sectional metrics tend not to represent the overall 
impact PRO trial data can have, since impact arises at different points in time [24, 
28]. In addition, impact is defined by each stakeholder group in a different way. For 
instance, academics considered impact in terms of number of publications and 
journal impact factor; policy-makers and regulators in terms of changes to healthcare 
policy and number of drug approvals. Therefore, further work should be done to 
determine whether the impact metrics identified capture the full impact of PRO trial 
data.  
Several methodological PRO-specific trial barriers were identified including poor 
quality trial design, suboptimal trial conduct and analysis and poor reporting quality. 
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Interestingly, funders did not raise poor quality trial design as an issue in their 
interviews but arguably should be concerned with the quality of the data collected, as 
it is considered a crucial barrier to the realisation of PRO trial impact downstream. 
Facilitators to maximise the impact of PRO trial data were discussed among 
stakeholders. Main facilitators highlighted were: mandatory inclusion of PRO data in 
funded trials and publications where appropriate; and the requirement to provide an 
implementation plan detailing the proposed use and impact of PRO clinical trial data 
as a direct requirement of funding. Additional facilitators included the importance of 
communicating PRO research widely, specifically at healthcare conferences hosted 
by organisations such as NCRI (The National Research Cancer Institute), ASCO 
(American Society of Clinical Oncology), and ESTRO (European Society for 
Radiotherapy & Oncology). It also felt important to empower patients by including 
them in the dissemination of PRO results at these healthcare conferences. 
Furthermore, the development of a UK law to enforce the collection of PRO data 
among clinical trials is considered as essential.  
Currently, PRO stakeholders are making concerted efforts to improve the collection 
of PRO data in oncology and cardiology areas. For instance, the European Society 
of Cardiology (ESC) has led initiatives to increase the prominence of PROs in 
cardiovascular research, which can be translated in benefits for patients, clinicians, 
payers and policy-makers [29]. The Food and Drug Administration (FDA) is currently 
developing patient-focused drug development (PFDD) guidance to address how 
stakeholders can collect and include PROs from patients and caregivers in the 
development and regulation of medical products [30]. In 2016, the EMA (European 
Medicine Agency) published Appendix 2 to the guideline on the evaluation of 
anticancer medicinal products in man. Appendix 2 provides a general overview of the 
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use of PRO endpoints in oncology studies and the value of this information from the 
regulatory perspective [31]. 
Additional initiatives include PROTEUS Consortium (Patient-Reported Outcomes 
Tools: Engaging Users & Stakeholders) [32], which aims to promote the uptake and 
use of tools to support high quality PRO trial data including tools such as: SPIRIT 
(Standard Protocol Items: Recommendations for Interventional Trials) PRO-
Extension [8]; ISOQOL Minimum Standards for PRO Measures in patient-centered 
outcomes and comparative effectiveness research [33]; SISAQOL (Setting 
International Standards in Analysing Patient-Reported Outcomes and Quality of Life 
Endpoints Data) [34]; CONSORT (Consolidated Standards of Reporting Trials) PRO-
Extension [35] Stakeholder-Driven, Evidence-Based Standards for Presenting PROs 
in Clinical Practice [36]; and Clinician’s Checklist for Reading  and Using an Article 
About PROs However, greater work needs to be done to capture PRO data in a 
rigorous efficient way across disciplines. Furthermore, key societies like Macmillan 
Cancer Support, ASCO and the NCRI are working on the endorsement of the 
dissemination of PRO trial studies, which might help to have a wider reach for 
spreading PRO trial results and consequently a further impact [37, 38].  
Strengths and limitations  
One of the key strengths of this study was the inclusion of 24 internationally 
recognised PRO experts. We consider the interviews captured all the core concepts 
around the impact of PRO trial data, which are presented above in four different 
themes. SCR, the interviewer, did not have a relationship with the participants; 
however, the wider team (MC/DK/AS) had previous collaborative links with some of 
the participants. To reduce the potential misinterpretation of data, the 
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multidisciplinary team provided support for the analysis and interpretation of the 
data. 
A further limitation was that since participants were recruited from a pool of 
stakeholders known to the research team, this might have limited the range and 
experience of stakeholders being interviewed. Moreover, 17 invitees decided not to 
participate in the research, which could have led to the exclusion of relevant 
individuals with a different perspective. Nonetheless, we attempted to interview as 
many participants as possible using purposive and snowball recruitment methods.  
Saturation within each stakeholder group would have been ideal but this was not 
possible. This would have allowed stronger conclusions to be drawn around the 
similarities and differences between each stakeholder group. Where there was 
appropriate evidence, similarities and differences were highlighted. Qualitative 
experts were involved to ensure congruence and structure at each stage of the 
research. 
Finally, the findings drawn from this study may be transferable to other researchers 
working on PRO clinical trials, who have knowledge of the area. This reflects the 
need to have a PRO expert as part of the clinical trial team and; make the research 
accessible and applicable across a broad spectrum of international stakeholders.  
Conclusion 
In this study, we have presented the perspectives of international PRO stakeholders 
on the impact of PRO trial data, impact measurement metrics, and barriers and 
facilitators to effectively maximise the impact of PRO trial data upon patients and 
society. Interviewees highlighted a range of potential impacts associated with PRO 
trial findings, most notably the influence on policy-making. However, there is a need 
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to find more comprehensive ways of measuring PRO impact. There a number of 
barriers that needs to be overcome to facilitate PRO impact. Stakeholders need to 
come together to address these challenges in order to optimise the uptake of PRO 
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This chapter summarises the key findings from this thesis, presents an interpretation 
of the results and their implications, outlines strengths and limitations and offers 
recommendations for future research. The aims of this thesis were: a) to synthesise 
existing methodological frameworks for healthcare research impact; b) determine the 
range of potential impact associated with PRO data collected in trials, identify 
potential PRO impact metrics and define common barriers to maximising PRO 
impact and; c) examine real-world evidence of PRO trial data impact and determine 
common facilitators aimed at maximising PRO trial data impact. 
There are a number of existing methodological frameworks used to capture 
healthcare research impact. However, there is a lack of consensus around the most 
effective methodological framework and impact metrics to measure the impact of 
healthcare research. This thesis therefore presents a collective summary of existing 
methodological impact frameworks and metrics, which funders may use to inform the 
measurement of healthcare research impact and researchers may use to inform 
study design decisions aimed at maximising the short-, medium-, and long-term 
impact of their research [1]. This consolidated framework has been used to underpin 
this doctoral research investigating common types of PRO trial impact, their 
measurement, and barriers and facilitators to realising such impact. Whilst a range of 
PRO-specific types of research impact have been proposed in the literature, real-
world evidence of such impact, although available, is currently limited (Chapter 4). 
Triangulation of both quantitative (Chapter 4) and qualitative (Chapter 5) data 
suggests there a number of potential barriers that need to be addressed in order to 
facilitate greater realisation of PRO trial impact in the future. 
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A mixed-method approach was used to address the aims of the thesis, which 
contribute to the research fields of research impact and PROs. Initially, a systematic 
review was conducted to explore existing methodological frameworks used to 
categorise the impact of healthcare research (Chapter 3; published August 9, 2017; 
28,461 views, Altmetric 300 and 15 citations to date). This work presented the novel 
‘pathways to research impact’ framework, which directly informed subsequent 
chapters. 
A second systematic review, informed by the previous framework, was conducted to 
assess the potential impact of PRO data collected from clinical trials, identify 
potential PRO impact metrics and identify barriers/facilitators to maximising PRO 
impact. Additionally, real-world evidence of PRO trial data was assessed based on 
the Research Excellence Framework (REF) 2014 impact case studies (Chapter 4).  
To gain better understanding of the findings in Chapter 4, a qualitative study 
involving international PRO stakeholders was undertaken. The study explored 
stakeholders’ perceptions on types of PRO trial impact, how to measure such impact 
and barriers and facilitators to maximise the realisation of PRO trial impact on 
patients and society (Chapter 5).  
Summary of findings 
A. Methodological frameworks for measuring the impact of 
healthcare research 
The systematic review (Chapter 3) identified the existence of 24 unique impact 
frameworks and incorporated these into a unified matrix: the ‘pathways to research 
impact’ methodological framework [1]. This framework may be used by funders and 
researchers to inform the measurement of research impact and study design 
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decisions to maximise the impact of research. The systematic review emphasised 
that users do not necessarily need to cover the entire methodological framework as 
research can impact on different areas. A systematic review (Chapter 4) and 
qualitative study (Chapter 5) further highlighted the lack of standardised impact 
metrics to capture PRO trial impact.   
B. PRO trial data: potential and real-world impact 
A second systematic review of the literature (Chapter 4) identified nine proposed 
types of PRO trial impact, which may lead to a range of benefits for patients and 
society. The types of impact identified as potentially attributable to PRO trial data 
included: informing clinical practice, clinical guidelines and health policy; supporting 
drug approval, pricing and reimbursement decisions and; informing clinical decision-
making, shared decision-making and consent for treatment. The most frequent of 
these impacts centred around PRO data informing clinical decision-making (69%). In 
addition, four impact metrics were proposed to measure the impact of PRO data: the 
number of pharmaceutical and promotional labelling claims, number of drug/device 
approvals and inform cost-effectiveness. The included publications outlined different 
barriers and facilitators around PRO trial design, conduct, analysis and reporting that 
may influence the subsequent impact of PRO trial data.  
Sixty-nine out of 209 REF case studies were included for assessment, of which 12 
(17%) demonstrated direct measurable PRO-related impact. A further 12 (17%) 
showed evidence of indirect PRO impact and an additional 45 (66%) provided no 
evidence of PRO impact. The most common types of direct PRO impact were: 
number of publications (n=12, 17%), changes to international guidelines (n=5, 7%), 
contribution to national guidelines (n=4, 6%), contribution to evidence of cost-
effectiveness (n=3, 4%) and informing drug approval (n=2, 3%). The lack of evidence 
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demonstrating directly attributable real-world PRO-related research impact can be 
attributed to the challenges associated to measuring research impact and PRO-
specific issues around design, conduct, analysis and reporting. 
International stakeholders were interviewed in order to develop a deeper 
understanding of the range of potential PRO impacts of clinical trials; barriers and 
facilitators to maximising the impact of PRO trial data. 
C. The impact of PRO trial data - perspectives from international 
stakeholders: a qualitative study  
The aim of the qualitative study (Chapter 5) was to explore the perceptions of PRO 
international stakeholders around the impact of PRO trial results on a) clinical 
practice, clinical guidelines, health policy, drug approval, pricing and reimbursement 
decisions, clinical decision-making, shared decision-making and consent for 
treatment. b) PRO impact metrics to measure such impact, and c) barriers and 
facilitators to effectively maximise the impact of PRO trial data upon patients and 
society. 
Based on the ‘pathways to research impact’ methodological framework [1], 
developed in Chapter 3, 24 semi-structured interviews were conducted with a range 
of key stakeholders. These included academic trialists, industry trialists, journal 
editors, clinicians, policy-makers and regulators, and funders. Interviewees 
expressed a collective view that PRO trial can influence primary research related 
impact; policy-making; health & health systems, health-related & societal impact and 
broader economic impact. Influence on policy-making was the most common type of 
impact discussed. The results demonstrated that stakeholders should broaden 
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collaboration in order to effectively tackle barriers to PRO trial impact and maximise 
the impact of PRO trial research. 
Interpretation and implications of findings 
A. Measuring healthcare research impact using methodological 
frameworks 
The systematic review presented in Chapter 3 highlighted different approaches to 
measuring research impact such as ‘quantitative’ metrics, case studies and 
approaches focusing on the interactions between stakeholders and researchers. 
‘Quantitative’ metrics are predominately used by funders as they can easily capture 
the impact of research; however, these metrics focus more on the dissemination of 
research rather than on the impact of the research findings [2, 3]. Therefore, the use 
of narrative case studies is required to present a detailed picture of the impact that 
cannot be attributed to impact metrics, such as the social interactions between 
stakeholders and researchers [4-8]. A limitation of this approach is that capturing 
these interactions can be labour-intensive and complex to verify and validate.  
These findings align to the narrative review results presented by Greenhalgh et al. 
[9] and the systematic review conducted by Banzi et al. [10]. The work of Greenhalgh 
et al. focused on determining the meaning of health research impact, how to 
measure such impact and reviewed strengths and limitations of different approaches 
to assess impact. The search strategy of this narrative review included publications 
between 2005 and 2014 [9]. The systematic review by Banzi et al. focused on 
identifying common approaches to research impact assessment, categories of 
impact and their respective indicators. The search strategy was limited to 1990-2009 
[10]. This systematic review did not include some relevant methodological 
frameworks, such as the SIAMPI model, Contribution Mapping, Exchange Model and 
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Research Contribution Framework, which are essential to measure the impact of 
healthcare research via interactions between stakeholders and researchers. 
Although both reviews presented similar results around methodological impact 
frameworks, their search strategies were based on earlier dates compared to our 
systematic review, which was from inception until 2017. Therefore, the systematic 
review presented in Chapter 3 presented for the first time a collective summary of 
five major impact categories across the 24 methodological frameworks identified into 
a single matrix. This matrix led to an exhaustive and comprehensive framework 
‘pathways to research impact’ to measure healthcare research impact. This novel 
matrix has the potential not to only inform stakeholders involved in healthcare 
research, but stakeholders involved in other research areas such as socio-economic 
impact of research. Furthermore, the ‘pathways to research impact’ framework could 
be further developed by including new types of impact and impact metrics, 
associated to a specific research area.   
B. PRO trial data: potential and real-world impact 
Chapter 4 highlighted methodological barriers and facilitators to realising PRO trial 
impact. These barriers and facilitators pertained to aspects surrounding PRO trial 
design, PRO trial conduct and analysis, PRO trial reporting and uptake of PRO trial 
results in practice. This is the first comprehensive review, which summarises 
potential PRO trial impact. Moreover, the findings regarding barriers to impact are 
consistent with a number of papers highlighting challenges with PRO trial design, 
analysis, reporting and interpretation. These methodological issues have been 
repeatedly noted in the literature and it is an important area to address to ensure 
PRO trial impact [11-17]. 
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Challenges associated with PRO data collection and non-reporting of PRO data may 
potentially lead to significant research waste, including waste of resources, time and 
patients’ efforts expended in PRO data collection, which may hinder the use of PRO 
data for patients and society [12, 18]. Greater consideration should be given at the 
design stage of a trial about how to maximise PRO trial data impact. Academic 
trialists, policy-makers and funders can all play an important role.  
In addition, a number of authors have emphasised the importance of adhering to 
existing PRO guidance, as it may help in the realisation of PRO trial data to benefit 
patients and society. A recent systematic evaluation of PRO protocol content and 
reporting in cancer clinical trials demonstrated a positive link between good design 
and reporting, which suggests that adherence to protocol guidelines could result in 
improved reporting [19]. In the last decade, PRO researchers have developed 
initiatives focused on the outcome and instrument selection, design, 
analysis/interpretation, reporting and presentation of PRO data, rather than focusing 
on the maximisation of PRO trial research and how to measure such impact. The 
selection of relevant outcomes, including PROs as appropriate, is an essential 
consideration in trial design. Figure 1 depicts the existing PRO initiatives, which 






•COMET (Core Outcome Measures in Effectiveness Trials) 
Instrument 
selection 
• COSMIN (COnsensus-based Standards for the selection of health 
Measurement INstruments) 
• ISOQOL Minimum Standards for PRO Measures in patient-centered 
outcomes and comparative effectiveness research*  
Design 
• SPIRIT- (Standard Protocol Items: Recommendations for Interventional 
Trial) PRO Extension*  
Analysis 
• SISAQOL (Setting International Standards in Analyzing Patient-
Reported Outcomes and Quality of Life Endpoints Data)* 
Reporting 
• CONSORT (Consolidated Standards of Reporting Trials) PRO 
Extension* 
Presentation 
• Stakeholder-driven, evidence-based standards for presenting PROs in 
clinical practice* 
Interpreting  
• Clinician's checklist for reading and using an article about patient-
reported outcomes* 
Figure 1. PRO initiatives 1  
  
                                                          
* Methodological tools promoted by the PROTEUS Consortium 
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The COMET (Core Outcome Measures in Effectiveness Trials) initiative has focused 
on the development and application of standardised core outcomes sets (COS) in 
clinical trials to provide guidance on the minimum requirements COS should be 
measured and reported in a clinical trial. Adherence to COMET guidance should lead 
to improved PRO trial design and selection of outcomes, whilst allowing PRO and 
clinical outcomes from trials to be compared, contrasted and combined [20].  
The COSMIN (COnsensus-based Standards for the selection of health Measurement 
INstruments) initiative provides guidance to researchers and clinicians in the choice 
of outcomes and outcome measurement instruments [16, 21]. ISOQOL 
recommendations focus on promoting the use of PRO measures to inform PRO 
comparative effectiveness research, which has the potential to improve effectiveness 
and efficiency of healthcare [22].  
The SPIRIT- (Standard Protocol Items: Recommendations for Interventional Trial) 
PRO Extension provides specific guidance around PRO protocol development [23]. 
SISAQOL (Setting International Standards in Analyzing Patient-Reported Outcomes 
and Quality of Life Endpoints Data) [24] aims at providing evidence to standardise 
the analysis and interpretation of PRO and quality of life data from cancer clinical 
trials, whereas CONSORT PRO Extension provides guidance to facilitate optimal 
reporting of trials in which PROs are primary or secondary outcomes, which could 
inform clinical practice and health policy by increasing clinician confidence in 
published PRO research [25].  
Other research initiatives have also set out to provide guidance around presentation 
and interpretation of PRO trial data. For instance, the stakeholder-driven, evidence-
based standards for presenting PRO data provides guidance on how to graphically 
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present PRO data to patients and clinicians [26], while the clinician's checklist for 
reading and using a PRO article aim at facilitating a tool for clinicians to assess a 
PRO clinical trial in order to make practice and treatment decisions for patients. 
Therefore, adherence to PRO-specific guidance has the potential to maximise real 
world PRO trial data by facilitating optimal selection of outcomes and instruments, 
design, analysis, reporting and presentation and interpreting of PRO trial data to 
PRO stakeholders and patients.   
These initiatives have involved a diverse range of international stakeholders (e.g. 
SPIRIT-PRO Extension involved clinical trial research personnel, PRO 
methodologists, funders, journal editors, policy makers and patient advocates, 
among others). However, evidence from Chapters 4 and 5 suggests that simply 
improving the results and presentation of PRO data through the adoption of the 
approaches above is unlikely to be sufficient to fully realise PRO impact.    
To date, there has been no other research study examining the impact of PRO trial 
data through the assessment of REF 2014 case studies. In 2015, a study conducted 
by Greenhalgh and Fahy [27] assessed the REF 2014 case studies submitted under 
the subpanel A2 (Public Health, Health Services Research and Primary Care) in 
order to explore the nature and mechanism of community-based health sciences 
impact. The main type of study examined was clinical trials. Although Greenhalgh 
and Fahy adopted a different search strategy and had different eligibility criteria to 
the research undertaken in Chapter 4 of this thesis, similar findings were presented. 
The research contained within the case studies was said to have mainly influenced 
clinical guidelines, healthcare policy and clinical practice and to a lesser extent, 
improvements in health outcomes and support cost savings [27]. Moreover, the 
structure of the REF 2014 case studies allowed capturing the impact of the research 
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and demonstrated impact on healthcare policy-making, which arises in the mid-term. 
However, the case studies did not capture research impact in the long-term such as 
health & health systems impact, health-related & societal impact and broader 
economic impact. Therefore, there is a need to assess real-world PRO trial impact 
and to do it through other methods that will capture such impact in the long-term in 
order to identify the pathways to PRO trial data impact. 
C. The impact of PRO trial data - perspectives from international 
stakeholders: a qualitative study  
While the systematic reviews identified some types of impact, impact metrics and 
barriers and facilitators associated with PRO impact, it was felt that deeper 
understanding was required. Therefore, a number of key international stakeholders 
were interviewed to gain a richer understanding of the issues. In Chapter 5, the 
international PRO stakeholders identified a number of key areas for PRO trial 
impact. These included policy-making, including changes to clinical healthcare 
practice and guidelines, drug approval, pharmaceutical and promotional labelling 
claims as the most common type of PRO trial impact. Health-related & societal 
impact and broader economic impact were the least common types of impact 
discussed by PRO international stakeholders.  
Moreover, international stakeholders discussed different PRO-specific 
methodological barriers and facilitators to maximising the impact of PRO trial results. 
These related to PRO trial design, PRO conduct and analysis, PRO reporting and 
dissemination, and uptake of PRO results. Stakeholders identified a number of areas 




Box 1. Key recommendations to maximise the impact of PRO trial data 
 
 
Although, several qualitative and quantitative metrics were proposed to measure the 
impact of PRO trial data; interviewees acknowledged that measuring the impact of 
PRO trial data through metrics is a challenging task, as it is not always possible to 
capture the full impact of PRO trial research. Therefore, further work is needed to 
identify and develop more comprehensive ways of measuring PRO impact. 
Unfortunately, poor quality PRO clinical trials have hampered the usage of PRO data 
not only in regulatory decision-making, but also in the use of clinical guidelines, and 
in clinical decision-making (Chapters 4 and 5). Thus, it is crucial to strengthen 
national and international collaborations to help in the realisation of PRO trial 
findings in practice and maximise the benefit to patients and society. 
 Development of a law or regulation to enforce the collection of PRO data*[Participant: 8] 
 Adherence to current PRO guidance*[Participant:11] **[12, 17, 28-33] 
 Development of PRO measures while considering health utilities for HTA 
use*[Participant:14] 
 Standardisation of PRO tools among therapeutic areas to improve analysis*[Participant:5] 
 Open access publications*[Participant:3,15,24]    
 Inclusion of a simple English summary of the trial results for use of patients*[Participant:15] 
 Availability of more journals publishing PRO trial data*[Participant:10]   
 Adequate funding for PRO trial components*[Participant:2,16,22]  
 Funders clearly expressing their positions about PROs and what they expect from the 
funded PRO research*[Participant:20,21,22]   
 Communication of PRO research widely through the involvement of key opinion 
leaders, specifically at healthcare conferences*[Participant:2,18,21]   
 Empowerment of patients through their involvement in discussions and dissemination 
of PRO trial results*[Participant:15,18,21,23,24] 
 Endorsement of PRO trial studies by key societies to disseminate PRO results and 
influence healthcare policy*[Participant:2,18] 
 
*Qualitative study participant numbers, see Chapter 5 for further details. 
**Systematic review in Chapter 3. References from the systematic review have been included in the 
reference list of this Chapter to inform the reader.  
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A Policy Review by Kluetz et al. [34] presented the perspectives of three 
international regulators around opportunities to incorporate PRO trial data in 
regulatory decision-making. The Policy Review highlighted the importance of 
improving international stakeholder collaboration and standardisation of PRO 
concepts, tools, methodology (SPIRIT-PRO extension [23]), analysis, presentation of 
PRO data and communication of PRO trial results to patients in order to incorporate 
PRO data into regulatory decision-making rigorously [34]. Although this Policy 
Review presented similar findings to the qualitative study (Chapter 5), the former did 
not capture the perspectives of other PRO stakeholders (e.g. academics, policy-
makers and funders), who could have emphasised different opportunities to 
incorporate PRO data into regulatory decision-making. In addition, the same review 
did not focus on determining PRO impact measurement metrics.  
One key stakeholder group that can help drive up standards are regulatory agencies 
such as the MHRA (The Medicines and Healthcare products Regulatory Agency, 
EMA (European Medicines Agency) and FDA (The Food and Drug Administration). It 
is therefore pleasing to see that incorporation of the patient experience into 
international regulatory decision-making and drug development is becoming of 
increasing interest [34, 35]. As an example, in 2016 the FDA 21st Century Cures Act 
(Cures Act) mandated the development and implementation of strategies to 
incorporate patient input in drug development, biological products, and devices in 
FDA's decision-making process [36]. Recent FDA initiative, PFDD (patient-focused 
drug development), is involving a range of stakeholders (patients, researchers, 
medical product developers and others) to incorporate the ‘voice’ of patient 
experience data of and other relevant information from patients and caregivers to 
inform the development of medical product and regulatory decision-making [37]. In 
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2016, the EMA also published Appendix 2 to the guideline on the evaluation of 
anticancer medicinal products in man [38], which aims at providing guidance around 
PRO selection and application in cancer clinical trials.  
Additional examples of broader international collaboration includes PROTEUS 
consortium (Patient-Reported Outcomes in Trials: Engaging Users and 
Stakeholders), funded by the Patient-Centred Outcomes Research Institute (PCORI) 
funded. PCORI aims to fund research to help patients and healthcare stakeholders 
make informed decisions surrounding healthcare treatments and disseminating and 
implementing research findings [39]. PROTEUS aims to engage key stakeholder 
groups who design, conduct, report, and benefit from PRO data in clinical trials. The 
initial work of this consortium is focused on dissemination and uptake of the tools 
detailed above (Figure 1) [40]; however this multi-stakeholder international 
consortium may offer opportunities to maximise PRO impact and uptake of data. 
Recommendations for future research  
The work presented in this thesis has highlighted the need for further research in 
order to measure and maximise the impact of PRO data from clinical trials. 
A. Applicability of methods to other medical research areas 
Methods undertaken within this thesis can be applied to further medical research 
areas (Chapters 3, 4 and 5) to better understand the impact realised by particular 
disciplines and identify barriers and facilitators to maximise impact. The majority of 
the literature cited in this thesis focused on oncology; however, PROs are used in 
multiple disciplines such as rheumatoid arthritis, orthopaedic procedures and 
cardiovascular conditions. Therefore, there is a need to optimise the use of PROs 
across medical disciplines, promote multi-stakeholder involvement whilst considering 
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collaboration across disciplines, especially important given patients with complex 
needs and multi-morbidities.  
B. Adherence to guidelines  
Evidence in this thesis suggests that suboptimal PRO trial 
design/implementation/analysis/reporting may have hampered the arising impact. 
Therefore, PRO researchers should adhere to existing international consensus 
guidelines around PROs to maximise the impact of PRO trial data (Box 1). There 
have been a number of trial guidelines that could be used to improve the quality of 
PRO use in clinical trials including: COMET [41], COSMIN [42],  SPIRIT-PRO 
Extension [23], SISAQOL [24], CONSORT PRO Extension [25], evidence-based 
recommendations for PRO data display to improve interpretability among clinicians, 
patients and PRO researchers [43, 44], clinician's checklist for reading and using an 
article about patient-reported outcomes [45], the FDA Guidance for Industry [46] and 
the EMA Appendix 2 [38].  
A further important area for research is to evaluate the uptake and use of these 
guidelines in practice [18]. Preliminary evidence suggests that the use of 
CONSORT/CONSORT-PRO guidance is associated with improved reporting [47, 
48]. However, a 2008 analysis of “Instructions to Authors” among 165 high impact 
medical journals demonstrated that only 38% included the original CONSORT 
statement within their instructions. Additionally, no more than 3% of the journals 
mentioned the CONSORT PRO Extension [47]. Measuring the uptake of PRO 
guidelines and impact on trial design, conduct and analysis, and reporting could be 
used by journal editors, funders and other key stakeholders to determine the 
potential benefits of endorsing and promoting guidelines. Potential methods to 
measure the uptake of PRO guidance include qualitative interviews among PRO 
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stakeholders, randomisation of authors or reviewers to the use of checklists or case 
studies focused on determining the impact of PRO data between trials that adhere 
and do not adhere to PRO guidance. Adherence to guidance should be adopted and 
enforced by academic and industry researchers, funders, IRBs (institutional review 
boards) and ethic committees and journal editors to minimise research waste and 
maximise the impact of PRO trial data for patients and society. Nonetheless, this is 
only a first step in generating impact by helping provide high quality PRO data. A 
further step in the generation of PRO impact is the development of a tool to aid 
stakeholders planning studies involving PROs to maximise PRO impact.  
C. Journals endorsement and enforcement to maximise the impact 
of PRO trial data 
Findings from this thesis (Chapters 4 and 5) suggested that optimal reporting of PRO 
trial is essential to maximise the uptake of PRO trial results in practice. However, it is 
essential that journal editors endorse and enforce the publication of PRO trial 
manuscript by making available more journals that support PRO research; provide 
open access to publications and include a simple English summary of the trial results  
specially for the use of patients (Box 1). An important area of research is to 
determine the number of current journals that endorse PRO trial research and 
identify those that incorporate patient and public partners in the peer-reviewed 
process to make PRO trial data more accessible to patients.  
D. Assessment of clinical guidelines to determine the impact of PRO 
trial data 
Assessment of clinical guidelines could also be used to determine the impact of PRO 
trial data in pharmaceutical labelling claims, clinical practice and healthcare 
outcomes. Although Chapter 4 demonstrated that direct and indirect PRO trial data 
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can lead to changes in clinical guidelines; the small number of REF impact case 
studies (n=24), that demonstrated this type of impact, limited the number of clinical 
guidelines assessed. Therefore, a comprehensive systematic review of clinical 
guidelines would provide further evidence on the uptake and use of PROs in 
guideline development, help identify clinical areas which are, or are not using PROs 
and provide useful case studies to help realise PRO impact. 
E. Routine clinical practice 
Increasingly, PROs are used in routine clinical practice. In England, the drive to 
using PROs in clinical practice has been increasing since 2009 with the National 
Health Service (NHS) PROMs programme, a way of assessing the quality of care 
delivered in the NHS from the patient’s perspective. PROs have been used for 
assessing the quality of care delivered by a number of elective procedures: hip and 
knee replacement, and up to September 2017, varicose vain and groin hernia 
surgery [49]. The availability of PRO tools for use in PROMs specific procedures, 
alongside the collection of clinical data, may lead to the routine collection of 
outcomes that matters to patients instead of focusing on functioning or disease 
specific aspects. Although there are plans to collect patient’s data in other 
procedures like coronary revascularisation, it is important to do more research in this 
field to improve healthcare services and identify priority healthcare areas that will 
benefit from the inclusion of PROs in routine clinical practice. The International 
Society for Quality of Life (ISOQOL) [50] has developed a user-friendly guide, User’s 
Guide for Implementing Patient-Reported Outcomes Assessment in Clinical Practice 
[51], to help clinicians in the incorporation of PROs in clinical practice. This guide 
might be used by other researchers as a step forward in the incorporation of PROs in 
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clinical practice. Box 2 presents an example of successful incorporation of PRO data 
in routine clinical practice. 
Box 2. Use of PRO data in routine practice 
Therefore, the collection of routine care PRO data (see Box 2) has the potential to 
inform clinical decision making by allowing early detection of problems, providing 
healthcare according to the patient’s needs and; prioritising patients who needed 
urgent care [54, 55]. Hence, the collection of PROs in routine practice has the 
potential to generate impact by promoting nuanced conversations between patients 
and clinicians, symptom management, improving patients’ health outcomes and 
better allocating healthcare resources.  
F. PRO impact metrics in routine clinical care 
While studies have suggested there is an impact from using PRO in clinical practice, 
it is important that the extent of that impact can be measured. Therefore, there is a 
need to identify impact metrics to determine the extent to which collecting PRO in 
routine clinical practice has an impact. A number of metrics have been identified 
through the systematic review presented in Chapter 4 and interviews with 
international stakeholders (Chapter 5). Suggested metrics could include reduced 
 
A US single centre randomised controlled trial evaluated whether systematic 
web based collection of symptoms during chemotherapy treatment improved 
health-related quality of life (HRQL), survival, quality-adjusted survival, 
emergency room (ER) visits and hospitalisation, among patients receiving 
chemotherapy for advanced solid tumours. HRQL improved among the 
intervention group (34% v 18%), as measured by the EQ-5D. In addition, ER 
admissions (34% v 41%; P = 0.02) and hospitalisations (45% v 49%; P = 0.08) 
were less frequent among the intervention group, a longer duration of 
chemotherapy treatment (mean, 8.2 v 6.3 months; P = 0.002) and superior 
quality-adjusted survival (mean of 8.7 v. 8.0 months; P = 0.004) [52, 53]. 
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hospitalisation and length of stay, reduction in the number of outpatient visits and 
emergency admissions, improvements in quality of life, reduction in the number of 
work loss days, and cost savings. PRO impact metrics in routine clinical care have 
the potential to inform hospital performance and patient satisfaction with care, 
identify unmet needs, inform future funding allocation and set healthcare priorities. 
Thus, further research is needed to develop a framework that captures the impact of 
PRO data in routine clinical care, which may benefit patients, funders and healthcare 
systems.  
A. Development of a law or regulation to enforce the collection of 
PRO data 
The development of a governance framework in the UK (Box 1), including legal 
requirement, to promote routine collection, processing and sharing of PROMs may 
have the potential to benefit society through the improvement of health outcomes 
and better use of healthcare resources. The first step to achieve this integrated 
approach is the establishment of a multi-stakeholder steering group including 
patients, clinicians, PRO methodologists, regulators, policy-makers and NHS digital 
to standardise PROM data and to establish good practice [55]. 
B. Development of PRO measures while considering health utilities 
for HTA use 
Frequently, the data used in HTA often does not include PRO data or includes high 
levels of missing PRO data. In other instances, HTA increasingly uses generic 
measures that may not be cover all the dimensions of relevance to some specific 
health conditions or uses disease specific measures, which require mapping to 
generate health utility values [56]. Therefore, further work is required to provide high 
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quality PRO data for HTA. In some instances, new disease specific utility measures 
may be warranted. 
C. Patient empowerment  
The involvement of patients and public advocates in the conduct of PRO trial 
research is essential as PRO data is considered the ‘voice of the patient’. Although 
patient advocacy groups are frequently involved in PRO trial research, it is essential 
to develop  user-friendly tools, training and support for patient advocates in the co-
design, conduct and analysis and reporting of PRO clinical trials.  
D. Clear funder position and adequate funding 
Chapter 5 demonstrated the need to specify the requirements and expectations, in 
terms of impact, funders have when funding PRO trial research. Funders highlighted 
the importance of academic and industry trialists to consider the impact of PRO trial 
research ‘a priori’ and beyond primary research related impact. However, there is a 
lack of guidance by PRO funders. Thus, an important area of research is to 
determine through qualitative methods, the requirements and expectations funders 
have when supporting PRO trial research. The findings could inform the 
development of guidelines for academic and industry trialists, which can help in the 
maximisation of resources and PRO trial data whilst benefiting patients and society. 
Strengths and limitations of the thesis 
There has been little previous research investigating the impact of PRO trial 
research or determining impact measurement metrics or facilitators to maximise 
PRO-specific research impact. Thus, the research within this thesis contributes novel 
findings to the research impact and PROs fields. The main strength of this doctoral 
thesis was the use of a mixed-methods approach to integrate qualitative and 
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quantitative research. The findings from the qualitative study (Chapter 5) shed 
additional light on the systematic reviews findings (Chapters 3 and 4) by providing 
further understanding on how to maximise the impact of PRO trial results to benefit 
patients and society.  
Findings have been disseminated in the following ways: 
 One publication in a high impact journal (PLOS Medicine, Chapter 3)  
 Publication of Chapter 4 in Health Quality of Life Outcomes Journal, Chapter 
4. 
 One oral presentation  
 Three poster presentations 
 Two public engagement activities: 1) ‘Research Changes Lives’, event hosted 
by the National Institute of Health Research (NIHR) and 2) Show and Tell 
event for the Centre for Trauma Sciences Research (CTSR) at the University 
of Birmingham. 
 A radio interview in the programme Practical Theorist by Birmingham 
Hospitals Broadcasting Network (BHBN) radio. 
 A two-day course hosted by Professor Calvert and the Centre for Patient 
Reported Outcomes Research (CPROR) at the University of Birmingham, 
November 2018.  
 Furthermore, the research was awarded the Michael K. O’Rouke Best PhD 
Publication for the College of Medical and Dental Sciences, University of 
Birmingham (Chapter 3). 
In addition, the work presented in Chapter 3 has attracted the attention of the 
Wellcome Trust, who are currently reviewing the socio-economic impact of research. 
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Their interest in the review has resulted in a number of meetings to discuss the 
findings from Chapter 3. 
A. Measuring healthcare research impact using methodological 
frameworks 
The findings of Chapters 3 and 4 were presented using PRISMA guidelines [57] for 
systematic reviews. The main strengths of this systematic review (Chapter 3) are 
adherence to Cochrane [58] and CRD guidelines [59] and development of a 
comprehensive search strategy, which extended through forwards/backwards 
citation searching, hand searching reference lists, and expert communication. 
Furthermore, a second reviewer independently conducted the search strategy, 
screened the retrieved studies, identified eligible studies and extracted data. The 
main limitation was the identification of over 50% of the included studies through 
different methods other than bibliographic database searching, representing poor 
indexing. Nonetheless, different bibliographic search techniques were adopted to 
avoid the exclusion of relevant articles. In addition, although the search strategies 
did not include language restrictions, non-English databases were not searched. 
Thus, the exclusion of potential articles was a possibility; however, every effort was  
made to include all the relevant articles. 
B. PRO trial data: potential and real-world impact 
The main strengths of this systematic review (Chapter 4) are again its rigorous 
methodology and inclusion of a second researcher at the different stages of the 
study. The main limitation was poor indexing, which means the exclusion of potential 
articles despite conducting an exhaustive search strategy. This was also mitigated 
by adopting different bibliographic search techniques. The systematic review results 
were limited to the assessment of only UK-based impact case studies, restricting the 
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generalisability of the results. Nonetheless, 30% of the trials assessed were 
categorised as international trials. In addition, it was not always possible to 
demonstrate direct attributable real world PRO-related impact, which can be partly 
explained by the challenges around measuring research impact. A further limitation 
was the inclusion of a high number of articles focused on oncology clinical trials, in 
the first section of the systematic review. The findings may require reproduction in 
other clinical fields to demonstrate generalisability. 
C. The impact of PRO trial data - perspectives from international 
stakeholders: a qualitative study  
In order to gain deeper understanding about types of PRO trial research impact, 
impact measurement metrics and barriers and facilitators to maximise PRO trial 
research impact; a qualitative study was conducted (Chapter 5). The qualitative 
study followed COREQ (Consolidated Criteria for Reporting Qualitative Research) 
and the ethical standards outlined by the University of Birmingham Code of Practice 
for Research [60, 61]. The main strength of the study was the inclusion of 24 
internationally recognised PRO stakeholders, which allowed exhaustive discussion 
of the topic. In addition, the conclusions of this qualitative study may be transferable 
to other stakeholders working on PRO clinical trials, who are knowledgeable about 
the topic. 
The study presented some limitations. Team members (MC/DK/AS) had a previous 
collaborative relationship with some of the interviewees, which could have limited the 
range and experience of stakeholders included and; potentially led to the 
misinterpretation of the data collected. To mitigate this, a multidisciplinary team 
including methodologists, clinical and non-clinical experts were involved to support 
the analysis and interpretation of the data. Furthermore, snowballing sampling was 
140 
 
implemented to recruit further participants outside the pool already known to the 
research team. The lack of saturation at stakeholder cohort level was also 
considered a limitation, as it would have allowed drawing stronger conclusions 
around similarities and differences between stakeholder groups. Although several 
stakeholders highlighted the impact of PRO trial from different clinical conditions 
such as irritable bowel syndrome, erectile dysfunction and rheumatoid arthritis, the 
majority of the interviewees discussed the impact of PRO data from oncology clinical 
trials. This should be taken into account when interpreting the results. Future 
qualitative work should be undertaken in differing clinical areas to explore alternate 
perspectives. 
Conclusions  
The studies presented in this thesis addressed three important topics within the area 
of PROs: a) the impact of PRO trial data, b) impact measurement metrics and c) 
barriers and facilitators to maximise the impact of PRO trial research on patients and 
society. 
The findings demonstrated that measuring the impact of PRO trial data is an 
essential exercise to demonstrate accountability, in terms of efficiency and 
effectiveness to funders, stakeholders, patients and society; to minimise research 
waste and; maximise the impact of PRO trial data through understanding the 
pathways to PRO trial impact. However, measuring PRO trial impact is challenging, 
as it is difficult to unpick the exact attribution of PRO data when combined with other 
‘clinical’ outcomes. Furthermore, to capture the impact of PRO trial data is necessary 
not to only use ‘quantitative’ metrics but to include qualitative methods and 
exhaustive case studies.  
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A key issue in maximising the impact of PRO trial data is the existence of 
methodological issues regarding the design, conduct, analysis and report of PRO 
clinical trials. There are a number of barriers that need to be addressed to realise the 
impact PRO trial data, comprising lack of adherence to PRO guidance, awareness of 
the importance of PRO and a law or regulation in the UK to enforce the collection of 
PRO trial data in clinical trials. Therefore, there is a need of a broader collaboration 
among national and international PRO stakeholders to maximise the benefit of PRO 
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Title  1 Identify the report as a systematic review, meta-analysis, or both.  Introduction 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
Abstract 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  Introduction, 
paragraph 6 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
Introduction, 
paragraph 6 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
NA 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
Methods, 
paragraph 2 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
Methods, 
paragraph 1 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated.  
S1_Appendix 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
Methods, 
paragraph 2 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 






Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
NA 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
NA 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  NA 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures 
of consistency (e.g., I
2
) for each meta-analysis.  
NA 
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Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication 
bias, selective reporting within studies).  
NA 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), 
if done, indicating which were pre-specified.  
NA 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram.  
Fig 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations.  
Table 1 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see 
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NA 
Results of individual 
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DISCUSSION   
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their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
Discussion 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
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Limitations 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 
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Conclusions 
FUNDING   
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Appendix 2.1 Search strategies 
Database: Ovid MEDLINE(R) <1946 to Dec Week 4 2018> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     (HRQL or HRQOL or QOL or quality of life or health index* or health indices or health 
profile* or health status or PROM* or PRO* or patient reported outcome* or self assessed 
outcome* or patient assessed outcome* or self report outcome* or health utility or patient 
report* outcome* or patient report* measure* patient report* assessment* or self report* 
outcome* or self* report* measure* or self* report* assessment* or self assess*).m_titl. 
(3561823) 
2     (policy or health policy* or decision making or healthcare policy or policy making or 
policy initiative or reimbursement decision*).m_titl. (48587) 
3     (clinical training or clinical practice or clinical guideline*).m_titl. (25046) 
4     (healthcare training or healthcare practice or healthcare guideline*).m_titl. (84) 
5     (labeling claims or labelling claims or promotional claims or drug approval).m_titl. (291) 
6     2 or 3 or 4 or 5 (73779) 
7     1 and 6 (9916) 
8     (impact or influence or inform or role or implication* or integrati* or relationship*).m_titl. 
(1100499) 











1     (HRQL or HRQOL or QOL or quality of life or health index* or health indices or health 
profile* or health status or PROM* or PRO* or patient reported outcome* or self assessed 
outcome* or patient assessed outcome* or self report outcome* or health utility or patient 
report* outcome* or patient report* measure* patient report* assessment* or self report* 
outcome* or self* report* measure* or self* report* assessment* or self assess*).m_titl. 
(4680609) 
2     (policy or health policy* or decision making or healthcare policy or policy making or 
policy initiative or reimbursement decision*).m_titl. (66221) 
3     (clinical training or clinical practice or clinical guideline*).m_titl. (37567) 
4     (healthcare training or healthcare practice or healthcare guideline*).m_titl. (116) 
5     (labeling claims or labelling claims or promotional claims or drug approval).m_titl. (513) 
6     2 or 3 or 4 or 5 (104122) 
7     1 and 6 (14192) 
8     (impact or influence or inform or role or implication* or integrati* or relationship*).m_titl. 
(1521903) 
















1     (HRQL or HRQOL or QOL or quality of life or health index* or health indices or health 
profile* or health status or PROM* or PRO* or patient reported outcome* or self assessed 
outcome* or patient assessed outcome* or self report outcome* or health utility or patient 
report* outcome* or patient report* measure* patient report* assessment* or self report* 
outcome* or self* report* measure* or self* report* assessment* or self assess*).m_titl. 
(51093) 
2     (policy or health policy* or decision making or healthcare policy or policy making or 
policy initiative).m_titl. (7457) 
3     (clinical training or clinical practice or clinical guideline*).m_titl. (1023) 
4     (healthcare training or healthcare practice or healthcare guideline*).m_titl. (16) 
5     (labeling claims or promotional claims).m_titl. (14) 
6     2 or 3 or 4 or 5 (8485) 
7     1 and 6 (1082) 
8     (impact or influence or inform or role or implication* or integrati* or relationship*).m_titl. 
(17743) 




Database: CINAHL+ <1979 to Dec 2018> 
Search Strategy: 
S1 TI HRQL or HRQOL or QOL or quality of life or health index* or health indices or health 
profile* or health status or PROM* or PRO* or patient reported outcome* or self assessed 
outcome* or patient assessed outcome* or self report outcome* or health utility or patient 
report* outcome* or patient report* measure* patient report* assessment* or self report* 
outcome* or self* report* measure* or self* report* assessment* or self assess* (662,953) 
160 
 
S2 TI policy or health policy* or decision making or healthcare policy or policy making or 
policy initiative (33,355) 
S3 TI clinical training or clinical practice or clinical guideline* (17,158) 
S4 TI healthcare training or healthcare practice or healthcare guideline* (956) 
S5 TI labeling claims or promotional claims (20) 
S6 S2 OR S3 OR S4 OR S5 (51,160) 
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search of reference lists and 
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Number of title/abstract records 
screened after 8,877 duplicates 
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Number of full-text records 
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Final number of full-text 
articles included (n=39) 
Number of records excluded 
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 Out of scope (n=2,195) 
 Routine clinical practice 
(n=68) 
 PRO impact not 
discussed (n=20) 
 Conference abstracts 
(n=288) 
Number of papers excluded 
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 PROs in routine care 
(n=10) 
 PRO as an intervention 
(n=6) 
Number of records identified 
(n=11,480) via:  
 MEDLINE (Ovid) (n=1,231) 
 EMBASE (n=1,920) 
 HMIC (n=140) 
 CINAHL+ (n=8,086) 
 Google Scholar (n=100) 
 Expert communication (n=3) 
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting 
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Appendix 2.4 - Potential types of PRO impact proposed 
Clinical practice, clinical guidelines and health policy 
A number of authors discussed the potential influence of PRO data on clinical practice, 
clinical guidelines and health policy. Several authors felt inclusion of PRO data on clinical 
guidelines may influence clinical practice, by fulfilling unmet clinical needs and leading to 
improved patient centre care by helping patients make more informed decisions on their 
care.44,48,51,58-60,76 Three studies suggested that the inclusion of PRO data in clinical 
guidelines might ensure wider acceptance of guideline recommendations among patients, 
while enhancing implementation through health policy.5,51,60 
Drug and device approval 
Authors reported that PRO data is increasingly used to provide evidence for drug and device 
approval, especially in oncology clinical trials.67,68 Eight publications discussed the influence 
of PRO data on pharmaceutical labelling claims by the Food and Drug Administration (FDA) 
and European Medicines Agency (EMA).44,62,64-70 One publication suggested that PRO data 
may inform drug and device approval through communication of the benefits and harms of 
the intervention has to clinicians, patients and other consumers.64 
An example given by one author was ruxolitinib (JakafiTM): an oral inhibitor to treat 
intermediate or high risk patients with myelofibrosis. This was the first FDA approved 
oncology drug that used PROs as an endpoint and followed FDA guidance to support a PRO 
based labelling claim.72 The oncology drug was approved based on reduction in spleen 
volume and improvement in symptom severity (e.g. weight loss, night sweats, itching, 
abdominal pain/discomfort, bone pain, cough, inactivity, early satiety and fever), as 
measured with the total symptom score (TSS). 
Pricing and reimbursement decisions 
Three publications discussed the influence of PRO data on pricing decisions57,66,71 and 
seven on drug reimbursement decisions.5,57,61,66,69,71,74 Authors suggested that inclusion of 
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PRO data provided valuable information regarding the risk-benefit of new interventions. 
Several authors postulated that within the context of oncology treatment, PRO data have the 
potential to identify costly events reported by the patients in the trials. Hence, interventions 
with reduced toxicity and added PRO benefit may influence payer decision-makers.72 
Additionally, the inclusion of patient advocacy groups may influence the availability of 
interventions, enhancing the patient healthcare experience by incorporating the ‘patient’s 
voice’ throughout payer decision-making.57,66 
One such example illustrated in the literature, is the decision by NICE (2015) to recommend 
the use of nintedanib plus docetaxel (Vargatef®) as a treatment option for locally advanced, 
metastatic or locally recurrent non-small-cell lung cancer of adenocarcinoma histology. The 
drug approval was primarily based on improved survival, minimal adverse drug effects and 
fewer detrimental effects on health-related quality of life (HRQL) compared to chemotherapy 
treatment. PRO data suggested that HRQL, as measured by the EuroQol-5 Dimension (EQ-
5D), the European Organization for Research and Treatment core quality of life 
questionnaire (EORTC QLC-C30) and the lung cancer–specific Quality of Life Questionnaire 
(EORTC QLQ-LC13) was similar in both groups.57,96 However, the PRO measures also 
demonstrated better pain management in patients randomised to nintedanib plus docetaxel 
based on information from the pain items.57,96 Therefore, additional drug benefits (symptom 
improvement and tolerability) were demonstrated through incorporation of PRO 
measurements into the trial, which similarly informed the reimbursement decision. The 
additional HRQL benefits may have been missed without the supporting PRO data within 
this trial. 
Clinical decision-making 
While reducing the impact of intervention toxicity and the impact on HRQL is important for 
drug labelling claims, it is also an important consideration for choices in clinical decision-
making. According to Goodwin et al. (2003), when there is medical treatment equivalence, 
HRQL data has the potential to inform clinical decision-making by prioritising quality of life 
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outcomes and reduction in toxicity when making clinical decisions.56 The authors conducted 
a systematic review of breast cancer clinical trials including PROs and determined that 
HRQL contributed to clinical decision-making within primary management (surgery, radiation 
and hormone therapies) and symptom control/supportive care setting of breast cancer. 
In total, 26 publications presented evidence that PRO data may help in the selection of 
optimal treatment, patient’s symptom experience and management, satisfaction with care 
and might predict prognosis, which has the potential to inform clinical decision-making based 
on the clinicians’ critical appraisal and interpretation of the available information.5,34-36,38-40,44-
61,74 
Dirven et al. (2014) conducted a systematic review of PRO clinical trials in patient with brain 
tumours and demonstrated that HRQL can be used alongside overall and progression-free 
survival to inform clinical decision-making. One of the clinical trials included determined that 
the combination of concomitant and adjuvant temozolomide and radiotherapy has become 
standard care for newly diagnosed patients with glioblastoma.53 This combination treatment 
led to significantly prolonged overall and progression-free survival, without negatively 
impacting HRQL in the long-term as measured with the EORTC QLQ-C30 questionnaire 
and Brain Cancer Module (BN-20).53     
Shared decision-making 
Shared decision-making is also important and four publications outlined the potential 
benefits of including PRO findings alongside other outcomes such as survival. This allowed 
patients and their clinicians to make an informed joint decision about treatment preferences 
and symptom management based on mutual understanding of treatment objectives and 
expectations.44,58,59,73 
Sztankay et al. (2017) assessed HRQL during first-line chemotherapy with pametrexed and 
maintenance therapy (MT) among patients with advanced non-small cell lung cancer.73 First-
line chemotherapy for patients with advanced non-small cell lung cancer was shown to 
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improve overall progression-free survival. However, as measured with the EORTC QLQ-C30 
and EORTC QLQ-LC13, MT compared to first-line chemotherapy was associated with lower 
HRQL and improvements in nausea, vomiting, appetite loss, constipation and pain. This 
information presented alongside survival data, allowed patients and clinicians to make real-
world informed joint decisions regarding treatment options. 
Informed treatment consent  
Consent for treatment refers to the authorisation given by a patient to receive a treatment, 
once the clinician presents a diagnosis, relevant treatment options and respective risks and 
benefits to the patient.97 Two publications discussed the influence of PRO trial data on 
treatment consent.39,49 Parameswaran et al. (2008) presented a systematic review of two 
randomised controlled trials, 9 longitudinal studies and 11 cross-sectional studies. The 
authors determined that only 11 studies presented data that was capable of effectively 
informing patient consent. This statement was based on the assessment of the HRQL 
methodology of the studies, through the HRQL checklist by Efficace et al. (2003).34 For 
instance, as measured with the EORTC-QLQ-C30 and MOS-SF36, one of the eleven 
studies determined that surgery for oesophageal cancer patients has a detrimental impact 
on quality of life in the postoperative stage (e.g. anastomic leaks, sepsis and cardiac and 
pulmonary complications) and in some cases; quality of life among survival patients does not 
improve in the long term.39 Therefore, communicating HRQL and clinical data to patients 
after the intervention could help inform patients about relevant information regarding 
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Final number of full-text articles 
included (n=69)* 
*Includes 3 duplicates (same 
case study submitted by two 
different institutions) 
Number of duplicates (n=0) 
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Number of records 
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 The case study does not 
present a clinical trial (n=17) 
 
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting 
Items for Systematic Reviews and Meta Analyses: The PRISMA Statement.  
171 
 












































































































































Appendix 3 - The impact of patient-reported outcomes (PROs) from 
clinical trials: perspectives from international stakeholders 
Appendix 3.1 - Topic Guide 
Consent: We are conducting the research how do patient-reported outcomes (PRO) trial 
results impact on future patient care and healthcare decisions. 
If you agree, I would like to ask you some questions about this topic. The interview should take 
up to 45 minutes. Your responses are confidential and anonymized. You are able to withdraw 
at any moment during and after the interview, up to 10 working days, without giving a reason.  
 Have you received and read the participant’s information sheet? 
 Do you have any questions about the study or the interview process? 
 Are you willing to proceed with the interview and allow me to use your anonymized data 
to inform the study and any future publications? 
 Would you like have access to any publications that will arise from this research project?   
o If YES to above 
 Are you happy for me to contact you using the email address you have provided? 
Aim of the study: i) to explore in depth the impact of patient-reported outcome (PRO) trial 
results on clinical practice, clinical guidelines and health policy development, drug approval, 
pricing and reimbursement decisions, clinical decision-making and consent for treatment. ii) To 
explore perceived barriers and facilitators of effective dissemination and impact on healthcare 
decisions and patient care. iii) Ultimately the results of this qualitative study will help inform the 
development of a PRO impact metrics framework.   
By impact, we mean a positive change or benefit on the economy, society, health, policy 
and academia. 
May I proceed with the first question?  
Background: 
1. Could you tell me about your background and area of research expertise? 
2. Do you think PROs trial findings have influenced your own practice? 
If yes, can you describe any examples? 
a. How did PRO trial findings influence your practice? 
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b. Why do you think it was important to incorporate PRO trial findings in your 
practice? 
c. Who benefited from the incorporation of PROs? 
d. What were the benefits of incorporating PRO trial findings in your practice? 
e. When was the trial conducted? 
If not, why do you think PRO trial findings do not influence your practice? 
3. Can you think of a specific PRO trial that has led to impact? This could be a trial you have 
been directly involved or you are aware of. 
a. Were you involved in this trial? 
b. When was the trial conducted? 
c. What was the clinical area? 
d. Tell me about the impact, why do you think this PRO trial led to impact? (pricing 
decisions, clinical practice, health policy, clinical guidelines or reimbursement 
decisions)  
e. How did PROs were incorporated? 
f. How did PROs facilitate the impact? 
4. In your experience, what is the most effective way to identify an impactful PRO clinical trial 
that could influence practice? If necessary, use as further explanation for the participant. 
Presentation of trial results at conferences, publications or clinical practice guidelines. 
a. Why do you think this is the most effective way? 
b. What are the advantages of this method? 
c. What are the disadvantages of this method? 
5. Can you think of any other effective ways to identify impactful PRO clinical trials? 
Barriers and facilitators:  
We are interested in identifying what barriers and facilitators influence the use of PRO trial 
findings in healthcare decisions and patient care. 
6. Thinking about the same impactful PRO trial, what were the main key things or 
facilitators that helped its dissemination and uptake in practice? 
If necessary, rephrase. Assuming we have a well conducted study. How can we maximise 
the benefit of PRO data and inform patient care and healthcare practice? 
7. Can you think of a clinical trial collecting PROs that has not led to PRO research impact? 
This can be a clinical trial you have been involved with or you are aware of. 
If yes, can you describe it? 
a. Why did not it lead to impact? 
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b. What were the consequences of conducting a PRO trial that does not lead to 
impact? 
c. What were the main limitations of those PRO trial findings? 
8. In your experience, what are the potential barriers that prevented the impact of the 
previous PRO trial results? If necessary, use as further explanation for the participant. 
These can be related to trial design, conduct and analysis, reporting, uptake in practice 
and other factors. 
9. Do you have any suggestions on how best to address barriers to realising PRO impact, or 
any ideas on how to proactively facilitate such impact? If necessary, use as further 
explanation for the participant. Clinicians training, use of SPIRIT and SPIRIT-PRO, 
CONSORT and CONSORT-PRO 
Impact metrics: 
We are interested in identifying ways that determine the impact of PRO trial findings have on 
healthcare decisions and patient care. 
6. How could we measure the impact of PRO trial findings on healthcare decisions and 
patient care in future? 
If necessary, example of metric: FDA – number of labelling claims approved 
7. What ways to measure impact would be the most representative?  
8. Do you think it would be useful to have a framework compiling the different measures 
mentioned?  
a. Why do you think it would be useful? 
b. What are the benefits of having this framework? 
c. Who do you think will benefit from this framework? 
d. How would it benefit you or other stakeholders involved in PRO trial research? 
e. When would it be useful for PRO trial research to use this framework? (Before or 
after conducting a trial) 
9. Are you aware that this sort of information is being captured? 
a. If yes, can you give me some examples? 
Conclusion: 
 I have no more questions, but I would like to give you the opportunity to add anything else 
we have not discussed. 
 Thank you for taking part in this interview. If you have any further questions or comments, 
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